CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

103234/5076

Trade Name: Epogen For Injection

Generic Name: Epoetin alfa

Sponsor: Amgen, Incorporated

Approval Date: November 10, 2004

Indications: For the treatment of anemia associated with CRF, including patients on dialysis (ESRD) and patients not on dialysis. Epogen is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients.


### Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
103234/5076

APPROVAL LETTER
Our STN: BL 103234-5076

Amgen, Incorporated  
Attention: Douglas Hunt  
Director, Regulatory Affairs  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799

Dear Mr. Hunt:

SUBMISSION TRACKING NUMBER (STN) BL 103234/5076 has been assigned to your recent supplement to your biologics license application for Epoetin alfa received on October 12, 2004. This acknowledgment recognizes that your submission is in the form of a Prior Approval Labeling Supplement as described under 21 CFR 601.12(f)(1).

Your request to supplement your biologics license application for Epoetin alfa to revise the package insert to update the Pharmacokinetics subsection of the Clinical Pharmacology section to include the pharmacokinetic profile of Epoetin alfa in neonates has been approved.

This fulfills your commitment to complete a literature search to find additional references to support the pharmacokinetic profile of Epoetin alfa in neonates as stated in commitment number 2 of the January 3, 1997, approval letter.

Pursuant to 21 CFR 201.57(f)(2), patient labeling must be reprinted at the end of the package insert. We request that the text of information distributed to patients be printed in a minimum of 10 point font.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

Please refer to <http://www.fda.gov/cder/biologics/default.htm> for important information regarding therapeutic biological products, including the addresses for submissions. Effective October 4, 2004, the new address for all submissions to this application is:

CDER Therapeutic Biological Products Document Room  
Center for Drug Evaluation and Research  
Food and Drug Administration  
12229 Wilkins Avenue  
Rockville, Maryland 20852
This information will be included in your biologics license application file.

Sincerely,

[Signature]

Patricia Keegan, M.D.
Director
Division of Therapeutic Biological Oncology Products
Office of Drug Evaluation VI
Center for Drug Evaluation and Research

Enclosures: Package Insert
APPLICATION NUMBER:
103234/5076

LABELING
DESCRIPTION
Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous erythropoietin. It has a molecular weight of 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.

EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution for intravenous (IV) or subcutaneous (SC) administration.

Single-dose, Preservative-free Vial: Each 1 mL of solution contains 2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8 mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.

Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1 mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic anhydride, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.

Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each 1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).

Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).

CLINICAL PHARMACOLOGY

Chronic Renal Failure Patients
Endogenous production of erythropoietin is normally regulated by the level of tissue oxygenation. Hypoxia and anemia generally increase the production of erythropoietin, which in turn stimulates erythropoiesis. In normal subjects, plasma erythropoietin levels range from 0.01 to 0.03 Units/mL and increase up to 100- to 1000-fold during hypoxia or anemia. In contrast, in patients with chronic renal failure (CRF), production of erythropoietin is impaired, and this erythropoietin deficiency is the primary cause of their anemia.

Chronic renal failure is the clinical situation in which there is a progressive and usually irreversible decline in kidney function. Such patients may manifest the sequelae of renal dysfunction, including anemia, but do not necessarily require regular dialysis. Patients with end-stage renal disease (ESRD) are those patients with CRF who require regular dialysis or kidney transplantation for survival.
EPOGEN® has been shown to stimulate erythropoiesis in anemic patients with CRF, including both patients on dialysis and those who do not require regular dialysis. The first evidence of a response to the three times weekly (TIW) administration of EPOGEN® is an increase in the reticulocyte count within 10 days, followed by increases in the red cell count, hemoglobin, and hematocrit, usually within 2 to 6 weeks. Because of the length of time required for erythropoiesis — several days for erythroid progenitors to mature and be released into the circulation — a clinically significant increase in hematocrit is usually not observed in less than 2 weeks and may require up to 6 weeks in some patients. Once the hematocrit reaches the suggested target range (30% to 36%), that level can be sustained by EPOGEN® therapy in the absence of iron deficiency and concurrent illnesses.

The rate of hematocrit increase varies between patients and is dependent upon the dose of EPOGEN®, within a therapeutic range of approximately 50 to 300 Units/kg TIW. A greater biologic response is not observed at doses exceeding 300 Units/kg TIW. Other factors affecting the rate and extent of response include availability of iron stores, the baseline hematocrit, and the presence of concurrent medical problems.

**Zidovudine-treated HIV-infected Patients**

Responsiveness to EPOGEN® in HIV-infected patients is dependent upon the endogenous serum erythropoietin level prior to treatment. Patients with endogenous serum erythropoietin levels ≤ 500 mUnits/mL, and who are receiving a dose of zidovudine ≤ 4200 mg/week, may respond to EPOGEN® therapy. Patients with endogenous serum erythropoietin levels > 500 mUnits/mL do not appear to respond to EPOGEN® therapy. In a series of four clinical trials involving 255 patients, 60% to 80% of HIV-infected patients treated with zidovudine had endogenous serum erythropoietin levels ≤ 500 mUnits/mL.

Response to EPOGEN® in zidovudine-treated HIV-infected patients is manifested by reduced transfusion requirements and increased hematocrit.

**Cancer Patients on Chemotherapy**

A series of clinical trials enrolled 131 anemic cancer patients who received EPOGEN® TIW and who were receiving cyclic cisplatin- or non cisplatin-containing chemotherapy. Endogenous baseline serum erythropoietin levels varied among patients in these trials with approximately 75% (n = 83/110) having endogenous serum erythropoietin levels ≤ 132 mUnits/mL, and approximately 4% (n = 4/110) of patients having endogenous serum erythropoietin levels > 500 mUnits/mL. In general, patients with lower baseline serum erythropoietin levels responded more vigorously to EPOGEN® than patients with higher baseline erythropoietin levels. Although no specific serum erythropoietin level can be stipulated above which patients would be unlikely to respond to EPOGEN® therapy, treatment of patients with grossly elevated serum erythropoietin levels (eg, > 200 mUnits/mL) is not recommended.

**Pharmacokinetics**

In adult and pediatric patients with CRF, the elimination half-life of plasma erythropoietin after intravenously administered EPOGEN® ranges from 4 to 13 hours. The half-life is approximately 20% longer in CRF patients than that in healthy subjects. After SC administration, peak plasma levels are achieved within 5 to 24 hours. The half-life is similar between adult patients with serum creatinine level greater than 3 and not on dialysis and those maintained on dialysis. The pharmacokinetic data indicate no apparent difference in EPOGEN® half-life among adult patients above or below 65 years of age.
The pharmacokinetic profile of EPOGEN® in children and adolescents appears to be similar to that of adults. Limited data are available in neonates. A study of 7 preterm very low birth weight neonates and 10 healthy adults given IV erythropoietin suggested that distribution volume was approximately 1.5 to 2 times higher in the preterm neonates than in the healthy adults, and clearance was approximately 3 times higher in the preterm neonates than in the healthy adults.

The pharmacokinetics of EPOGEN® have not been studied in HIV-infected patients.

A pharmacokinetic study comparing 150 Units/kg SC TIW to 40,000 Units SC weekly dosing regimen was conducted for 4 weeks in healthy subjects (n = 12) and for 6 weeks in anemic cancer patients (n = 32) receiving cyclic chemotherapy. There was no accumulation of serum erythropoietin after the 2 dosing regimens during the study period. The 40,000 Units weekly regimen had a higher C_{max} (3- to 7-fold), longer T_{max} (2- to 3-fold), higher AUC_{0-168h} (2- to 3-fold) of erythropoietin and lower clearance (50%) than the 150 Units/kg TIW regimen. In anemic cancer patients, the average t_{1/2} was similar (40 hours with range of 16 to 67 hours) after both dosing regimens. After the 150 Units/kg TIW dosing, the values of T_{max} and clearance are similar (13.3 ± 12.4 vs. 14.2 ± 6.7 hours, and 20.2 ± 15.9 vs. 23.6 ± 9.5 mL/h/kg) between Week 1 when patients were receiving chemotherapy (n = 14) and Week 3 when patients were not receiving chemotherapy (n = 4). Differences were observed after the 40,000 Units weekly dosing with longer T_{max} (38 ± 18 hours) and lower clearance (9.2 ± 4.7 mL/h/kg) during Week 1 when patients were receiving chemotherapy (n = 18) compared with those (22 ± 4.5 hours, 13.9 ± 7.6 mL/h/kg) during Week 3 when patients were not receiving chemotherapy (n = 7).

The bioequivalence between the 10,000 Units/mL citrate-buffered Epoetin alfa formulation and the 40,000 Units/mL phosphate-buffered Epoetin alfa formulation has been demonstrated after SC administration of single 750 Units/kg doses to healthy subjects.

INDICATIONS AND USAGE

Treatment of Anemia of Chronic Renal Failure Patients

EPOGEN® is indicated for the treatment of anemia associated with CRF, including patients on dialysis (ESRD) and patients not on dialysis. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients.

Non-dialysis patients with symptomatic anemia considered for therapy should have a hemoglobin less than 10 g/dL.

EPOGEN® is not intended for patients who require immediate correction of severe anemia. EPOGEN® may obviate the need for maintenance transfusions but is not a substitute for emergency transfusion.

Prior to initiation of therapy, the patient's iron stores should be evaluated. Transferrin saturation should be at least 20% and ferritin at least 100 ng/mL. Blood pressure should be adequately controlled prior to initiation of EPOGEN® therapy, and must be closely monitored and controlled during therapy.

EPOGEN® should be administered under the guidance of a qualified physician (see DOSAGE AND ADMINISTRATION).

Treatment of Anemia in Zidovudine-treated HIV-infected Patients
EPOGEN® is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

EPOGEN®, at a dose of 100 Units/kg TIW, is effective in decreasing the transfusion requirement and increasing the red blood cell level of anemic, HIV-infected patients treated with zidovudine, when the endogenous serum erythropoietin level is ≤ 500 mUnits/mL and when patients are receiving a dose of zidovudine ≤ 4200 mg/week.

**Treatment of Anemia in Cancer Patients on Chemotherapy**

EPOGEN® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. EPOGEN® is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. EPOGEN® is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

**Reduction of Allogeneic Blood Transfusion in Surgery Patients**

EPOGEN® is indicated for the treatment of anemic patients (hemoglobin >10 to ≤ 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. EPOGEN® is indicated for patients at high risk for perioperative transfusions with significant, anticipated blood loss. EPOGEN® is not indicated for anemic patients who are willing to donate autologous blood. The safety of the perioperative use of EPOGEN® has been studied only in patients who are receiving anticoagulant prophylaxis.

**CLINICAL EXPERIENCE: RESPONSE TO EPOGEN®**

**Chronic Renal Failure Patients**

Response to EPOGEN® was consistent across all studies. In the presence of adequate iron stores (see IRON EVALUATION), the time to reach the target hematocrit is a function of the baseline hematocrit and the rate of hematocrit rise.

The rate of increase in hematocrit is dependent upon the dose of EPOGEN® administered and individual patient variation. In clinical trials at starting doses of 50 to 150 Units/kg TIW, adult patients responded with an average rate of hematocrit rise of:

<table>
<thead>
<tr>
<th>Starting Dose (TIW IV)</th>
<th>Hematocrit Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 Units/kg</td>
<td>0.11 Points/Day</td>
</tr>
<tr>
<td>100 Units/kg</td>
<td>0.18 Points/Day</td>
</tr>
<tr>
<td>150 Units/kg</td>
<td>0.25 Points/Day</td>
</tr>
</tbody>
</table>

Over this dose range, approximately 95% of all patients responded with a clinically significant increase in hematocrit, and by the end of approximately 2 months of therapy virtually all patients were transfusion-independent. Changes in the quality of life of adult patients treated with EPOGEN® were assessed as part of a phase 3 clinical trial. Once the target hematocrit (32% to 38%) was achieved, statistically significant improvements were demonstrated for most quality of life parameters measured, including energy and activity level, functional ability, sleep and eating behavior, health status,
satisfaction with health, sex life, well-being, psychological effect, life satisfaction, and happiness. Patients also reported improvement in their disease symptoms. They showed a statistically significant increase in exercise capacity (VO₂ max), energy, and strength with a significant reduction in aching, dizziness, anxiety, shortness of breath, muscle weakness, and leg cramps.²¹

Adult Patients on Dialysis: Thirteen clinical studies were conducted, involving IV administration to a total of 1010 anemic patients on dialysis for 986 patient-years of EPOGEN® therapy. In the three largest of these clinical trials, the median maintenance dose necessary to maintain the hematocrit between 30% to 36% was approximately 75 Units/kg TIW. In the US multicenter phase 3 study, approximately 65% of the patients required doses of 100 Units/kg TIW, or less, to maintain their hematocrit at approximately 35%. Almost 10% of patients required a dose of 25 Units/kg, or less, and approximately 10% required a dose of more than 200 Units/kg TIW to maintain their hematocrit at this level.

A multicenter unit dose study was also conducted in 119 patients receiving peritoneal dialysis who self-administered EPOGEN® subcutaneously for approximately 109 patient-years of experience. Patients responded to EPOGEN® administered SC in a manner similar to patients receiving IV administration.²²

Pediatric Patients on Dialysis: One hundred twenty-eight children from 2 months to 19 years of age with CRF requiring dialysis were enrolled in 4 clinical studies of EPOGEN®. The largest study was a placebo-controlled, randomized trial in 113 children with anemia (hematocrit ≤ 27%) undergoing peritoneal dialysis or hemodialysis. The initial dose of EPOGEN® was 50 Units/kg IV or SC TIW. The dose of study drug was titrated to achieve either a hematocrit of 30% to 36% or an absolute increase in hematocrit of 6 percentage points over baseline.

At the end of the initial 12 weeks, a statistically significant rise in mean hematocrit (9.4% vs 0.9%) was observed only in the EPOGEN® arm. The proportion of children achieving a hematocrit of 30%, or an increase in hematocrit of 6 percentage points over baseline, at any time during the first 12 weeks was higher in the EPOGEN® arm (96% vs 58%). Within 12 weeks of initiating EPOGEN® therapy, 92.3% of the pediatric patients were transfusion-independent as compared to 65.4% who received placebo. Among patients who received 36 weeks of EPOGEN®, hemodialysis patients required a higher median maintenance dose (167 Units/kg/week [n = 28] vs 76 Units/kg/week [n = 36]) and took longer to achieve a hematocrit of 30% to 36% (median time to response 69 days vs 32 days) than patients undergoing peritoneal dialysis.

Patients With CRF Not Requiring Dialysis
Four clinical trials were conducted in patients with CRF not on dialysis involving 181 patients treated with EPOGEN® for approximately 67 patient-years of experience. These patients responded to EPOGEN® therapy in a manner similar to that observed in patients on dialysis. Patients with CRF not on dialysis demonstrated a dose-dependent and sustained increase in hematocrit when EPOGEN® was administered by either an IV or SC route, with similar rates of rise of hematocrit when EPOGEN® was administered by either route. Moreover, EPOGEN® doses of 75 to 150 Units/kg per week have been shown to maintain hematocrits of 36% to 38% for up to 6 months. Correcting the anemia of progressive renal failure will allow patients to remain active even though their renal function continues to decrease.²³-²⁴

Zidovudine-treated HIV-infected Patients
EPOGEN® has been studied in four placebo-controlled trials enrolling 297 anemic (hematocrit < 30%) HIV-infected (AIDS) patients receiving concomitant therapy with zidovudine (all patients were treated with Epoetin alfa manufactured by Amgen Inc.). In the subgroup of patients (89/125 EPOGEN® and 88/130 placebo) with prestudy endogenous serum erythropoietin levels ≤ 500 mUnits/mL, EPOGEN® reduced the mean cumulative number of units of blood transfused
per patient by approximately 40% as compared to the placebo group. Among those patients who required transfusions at baseline, 43% of patients treated with EPOGEN® versus 18% of placebo-treated patients were transfusion-independent during the second and third months of therapy. EPOGEN® therapy also resulted in significant increases in hematocrit in comparison to placebo. When examining the results according to the weekly dose of zidovudine received during month 3 of therapy, there was a statistically significant (p < 0.003) reduction in transfusion requirements in patients treated with EPOGEN® (n = 51) compared to placebo treated patients (n = 54) whose mean weekly zidovudine dose was ≤ 4200 mg/week.25

Approximately 17% of the patients with endogenous serum erythropoietin levels ≤ 500 mUnits/mL receiving EPOGEN® in doses from 100 to 200 Units/kg TIW achieved a hematocrit of 38% without administration of transfusions or significant reduction in zidovudine dose. In the subgroup of patients whose prestudy endogenous serum erythropoietin levels were > 500 mUnits/mL, EPOGEN® therapy did not reduce transfusion requirements or increase hematocrit, compared to the corresponding responses in placebo-treated patients.

In a 6 month open-label EPOGEN® study, patients responded with decreased transfusion requirements and sustained increases in hematocrit and hemoglobin with doses of EPOGEN® up to 300 Units/kg TIW.25-27

Responsiveness to EPOGEN® therapy may be blunted by intercurrent infectious/inflammatory episodes and by an increase in zidovudine dosage. Consequently, the dose of EPOGEN® must be titrated based on these factors to maintain the desired erythropoietic response.

Cancer Patients on Chemotherapy

Three-Times Weekly (TIW) Dosing

EPOGEN® administered TIW has been studied in a series of six placebo-controlled, double-blind trials that enrolled 131 anemic cancer patients receiving EPOGEN® or matching placebo. Across all studies, 72 patients were treated with concomitant non cisplatin-containing chemotherapy regimens and 59 patients were treated with concomitant cisplatin-containing chemotherapy regimens. Patients were randomized to EPOGEN® 150 Units/kg or placebo subcutaneously TIW for 12 weeks in each study.

The results of the pooled data from these six studies are shown in the table below. Because of the length of time required for erythropoiesis and red cell maturation, the efficacy of EPOGEN® (reduction in proportion of patients requiring transfusions) is not manifested until 2 to 6 weeks after initiation of EPOGEN®.

<table>
<thead>
<tr>
<th>Chemotherapy Regimen</th>
<th>On Study</th>
<th>During Months 2 and 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EPOGEN®</td>
<td>Placebo</td>
</tr>
<tr>
<td>Regimens without cisplatin</td>
<td>44% (15/34)</td>
<td>44% (16/36)</td>
</tr>
<tr>
<td>Regimens containing cisplatin</td>
<td>50% (14/28)</td>
<td>63% (19/30)</td>
</tr>
<tr>
<td>Combined</td>
<td>47% (29/62)</td>
<td>53% (35/66)</td>
</tr>
</tbody>
</table>

*Limited to patients remaining on study at least 15 days (1 patient excluded from EPOGEN®, 2 patients excluded from placebo).

Proportion of Patients Transfused During Chemotherapy (Efficacy Population*)
Intensity of chemotherapy in the above trials was not directly assessed, however the degree and timing of neutropenia was comparable across all trials. Available evidence suggests that patients with lymphoid and solid cancers respond similarly to EPOGEN® therapy, and that patients with or without tumor infiltration of the bone marrow respond similarly to EPOGEN® therapy.

**Weekly (QW) Dosing**

EPOGEN® was also studied in a placebo-controlled, double-blind trial utilizing weekly dosing in a total of 344 anemic cancer patients. In this trial, 61 (35 placebo arm and 26 in the EPOGEN® arm) patients were treated with concomitant cisplatin containing regimens and 283 patients received concomitant chemotherapy regimens that did not contain cisplatinum. Patients were randomized to EPOGEN® 40,000 Units weekly (n = 174) or placebo (n = 170) SC for a planned treatment period of 16 weeks. If hemoglobin had not increased by > 1 g/dL, after 4 weeks of therapy or the patient received RBC transfusion during the first 4 weeks of therapy, study drug was increased to 60,000 Units weekly. Forty-three percent of patients in the Epoetin alfa group required and increase in EPOGEN® dose to 60,000 Units weekly.  

Results demonstrated that EPOGEN® therapy reduced the proportion of patients transfused in day 29 through week 16 of the study as compared to placebo. Twenty-five patients (14%) in the EPOGEN® group received transfusions compared to 48 patients (28%) in the placebo group (p = 0.0010) between day 29 and week 16 or the last day on study.

Comparable intensity of chemotherapy for patients enrolled in the two study arms was suggested by similarities in mean dose and frequency of administration for the 10 most commonly administered chemotherapy agents, and similarity in the incidence of changes in chemotherapy during the trial in the two arms.

**Surgery Patients**

EPOGEN® has been studied in a placebo-controlled, double-blind trial enrolling 316 patients scheduled for major, elective orthopedic hip or knee surgery who were expected to require ≥ 2 units of blood and who were not able or willing to participate in an autologous blood donation program. Based on previous studies which demonstrated that pretreatment hemoglobin is a predictor of risk of receiving transfusion,20,28 patients were stratified into one of three groups based on their pretreatment hemoglobin [≤ 10 (n = 2), > 10 to ≤ 13 (n = 96), and > 13 to ≤ 15 g/dL (n = 218)] and then randomly assigned to receive 300 Units/kg EPOGEN®, 100 Units/kg EPOGEN® or placebo by SC injection for 10 days before surgery, on the day of surgery, and for 4 days after surgery. 18 All patients received oral iron and a low-dose post-operative warfarin regimen.18
Treatment with EPOGEN® 300 Units/kg significantly (p = 0.024) reduced the risk of allogeneic transfusion in patients with a pretreatment hemoglobin of > 10 to ≤ 13; 5/31 (16%) of EPOGEN® 300 Units/kg, 6/26 (23%) of EPOGEN® 100 Units/kg, and 13/29 (45%) of placebo-treated patients were transfused.¹⁸ There was no significant difference in the number of patients transfused between EPOGEN® (9% 300 Units/kg, 6% 100 Units/kg) and placebo (13%) in the > 13 to ≤ 15 g/dL hemoglobin stratum. There were too few patients in the ≤ 10 g/dL group to determine if EPOGEN® is useful in this hemoglobin strata. In the > 10 to ≤ 13 g/dL pretreatment stratum, the mean number of units transfused per EPOGEN®-treated patient (0.45 units blood for 300 Units/kg, 0.42 units blood for 100 Units/kg) was less than the mean transfused per placebo-treated patient (1.14 units) (overall p = 0.028). In addition, mean hemoglobin, hematocrit, and reticulocyte counts increased significantly during the presurgery period in patients treated with EPOGEN®.¹⁸

EPOGEN® was also studied in an open-label, parallel-group trial enrolling 145 subjects with a pretreatment hemoglobin level of > 10 to ≤ 13 g/dL who were scheduled for major orthopedic hip or knee surgery and who were not participating in an autologous program.¹⁹ Subjects were randomly assigned to receive one of two SC dosing regimens of EPOGEN® (600 Units/kg once weekly for 3 weeks prior to surgery and on the day of surgery, or 300 Units/kg once daily for 10 days prior to surgery, on the day of surgery and for 4 days after surgery). All subjects received oral iron and appropriate pharmacologic anticoagulation therapy.

From pretreatment to presurgery, the mean increase in hemoglobin in the 600 Units/kg weekly group (1.44 g/dL) was greater than observed in the 300 Units/kg daily group.¹⁹ The mean increase in absolute reticulocyte count was smaller in the weekly group (0.11 x 10⁶/mm³) compared to the daily group (0.17 x 10⁶/mm³). Mean hemoglobin levels were similar for the two treatment groups throughout the postsurgical period.

The erythropoietic response observed in both treatment groups resulted in similar transfusion rates [11/69 (16%) in the 600 Units/kg weekly group and 14/71 (20%) in the 300 Units/kg daily group].¹⁹ The mean number of units transfused per subject was approximately 0.3 units in both treatment groups.

**CONTRAINDICATIONS**

EPOGEN® is contraindicated in patients with:
1. Uncontrolled hypertension.
2. Known hypersensitivity to mammalian cell-derived products.
3. Known hypersensitivity to Albumin (Human).

**WARNINGS**

**Pediatric Use**
The multidose preserved formulation contains benzyl alcohol. Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in premature infants which are sometimes fatal.

**Thrombotic Events and Increased Mortality**
A randomized, prospective trial of 1265 hemodialysis patients with clinically evident cardiac disease (ischemic heart disease or congestive heart failure) was conducted in which patients were assigned to EPOGEN® treatment targeted to a maintenance hematocrit of either 42 ± 3% or 30 ± 3%. Increased mortality was observed in 634 patients randomized to a target hematocrit of 42% (221 deaths [35% mortality]) compared to 631 patients targeted to remain at a hematocrit of 30% (185 deaths [29% mortality]). The reason for the increased mortality observed in these studies is unknown, however, the incidence of non-fatal myocardial infarctions (3.1% vs 2.3%), vascular access thromboses (39% vs 29%), and all other thrombotic events (22% vs 18%) were also higher in the group randomized to achieve a hematocrit of 42%.

Increased mortality was also observed in a randomized placebo-controlled study of EPOGEN® in adult patients who did not have CRF who were undergoing coronary artery bypass surgery (7 deaths in 126 patients randomized to EPOGEN® versus no deaths among 56 patients receiving placebo). Four of these deaths occurred during the period of study drug administration and all four deaths were associated with thrombotic events. While the extent of the population affected is unknown, in patients at risk for thrombosis, the anticipated benefits of EPOGEN® treatment should be weighed against the potential for increased risks associated with therapy.

In a randomized, prospective trial conducted with another Epoetin alfa product, in 939 women with metastatic carcinoma of the breast who were receiving chemotherapy, patients were assigned to receive either Epoetin alfa or placebo for up to a year, in a weekly schedule, with the primary goal of showing improved survival and improved quality of life in the Epoetin alfa treatment arm. This study utilized a treatment strategy designed to maintain hemoglobin levels of 12 to 14 g/dL (hematocrit 38 to 42%). Increased mortality in the first 4 months after randomization was observed among 469 patients who received the erythropoietin product [41 deaths (8.7% mortality)] compared to 470 patients who received placebo [16 deaths (3.4% mortality)]. In the first four months of the study, the incidence of fatal thrombotic vascular events (1.1% vs 0.2%) and death attributed to disease progression (6.0% vs 2.8%) were both higher in the group randomized to receive Epoetin alfa as compared to placebo. Based on Kaplan-Meier estimates, the proportion of subjects surviving at 12 months after randomization was lower in the Epoetin alfa group than in the placebo group (70% vs 76%), p = 0.012, log rank. However, due to insufficient monitoring and data collection, reliable comparisons cannot be made concerning the effect of Epoetin alfa on overall time to disease progression, progression-free survival, and overall survival.

**Pure Red Cell Aplasia**

Pure red cell aplasia (PRCA), in association with neutralizing antibodies to native erythropoietin, has been observed in patients treated with recombinant erythropoietins. PRCA has been reported in a limited number of patients exposed to EPOGEN®. This has been reported predominantly in patients with CRF. Any patient with loss of response to EPOGEN® should be evaluated for the etiology of loss of effect (see PRECAUTIONS: LACK OR LOSS OF RESPONSE). EPOGEN® should be discontinued in any patient with evidence of PRCA and the patient evaluated for the presence of binding and neutralizing antibodies to EPOGEN® native erythropoietin, and any other recombinant erythropoietin administered to the patient. Amgen should be contacted to assist in this evaluation. In patients with PRCA secondary to neutralizing antibodies to erythropoietin, EPOGEN® should not be administered and such patients should not be switched to another product as anti-erythropoietin antibodies cross-react with other erythropoietins (see ADVERSE REACTIONS).

**Albumin (Human)**

EPOGEN® contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin.
Chronic Renal Failure Patients

Hypertension: Patients with uncontrolled hypertension should not be treated with EPOGEN®; blood pressure should be controlled adequately before initiation of therapy. Up to 80% of patients with CRF have a history of hypertension. Although there does not appear to be any direct pressor effects of EPOGEN®, blood pressure may rise during EPOGEN® therapy. During the early phase of treatment when the hematocrit is increasing, approximately 25% of patients on dialysis may require initiation of, or increases in, antihypertensive therapy. Hypertensive encephalopathy and seizures have been observed in patients with CRF treated with EPOGEN®.

Special care should be taken to closely monitor and aggressively control blood pressure in patients treated with EPOGEN®. Patients should be advised as to the importance of compliance with antihypertensive therapy and dietary restrictions. If blood pressure is difficult to control by initiation of appropriate measures, the hemoglobin may be reduced by decreasing or withholding the dose of EPOGEN®. A clinically significant decrease in hemoglobin may not be observed for several weeks.

It is recommended that the dose of EPOGEN® be decreased if the hemoglobin increase exceeds 1 g/dL in any 2-week period, because of the possible association of excessive rate of rise of hemoglobin with an exacerbation of hypertension. In CRF patients on hemodialysis with clinically evident ischemic heart disease or congestive heart failure, the hemoglobin should be managed carefully, not to exceed 12 g/dL (see THROMBOTIC EVENTS).

Seizures: Seizures have occurred in patients with CRF participating in EPOGEN® clinical trials.

In adult patients on dialysis, there was a higher incidence of seizures during the first 90 days of therapy (occurring in approximately 2.5% of patients) as compared with later timepoints.

Given the potential for an increased risk of seizures during the first 90 days of therapy, blood pressure and the presence of premonitory neurologic symptoms should be monitored closely. Patients should be cautioned to avoid potentially hazardous activities such as driving or operating heavy machinery during this period.

While the relationship between seizures and the rate of rise of hemoglobin is uncertain, it is recommended that the dose of EPOGEN® be decreased if the hemoglobin increase exceeds 1 g/dL in any 2-week period.

Thrombotic Events: During hemodialysis, patients treated with EPOGEN® may require increased anticoagulation with heparin to prevent clotting of the artificial kidney (see ADVERSE REACTIONS for more information about thrombotic events).

Other thrombotic events (eg, myocardial infarction, cerebrovascular accident, transient ischemic attack) have occurred in clinical trials at an annualized rate of less than 0.04 events per patient year of EPOGEN® therapy. These trials were conducted in adult patients with CRF (whether on dialysis or not) in whom the target hematocrit was 32% to 40%. However, the risk of thrombotic events, including vascular access thrombosis, was significantly increased in adult patients with ischemic heart disease or congestive heart failure receiving EPOGEN® therapy with the goal of reaching a normal hematocrit (42%) as compared to a target hematocrit of 30%. Patients with pre-existing cardiovascular disease should be monitored closely.

Zidovudine-treated HIV-infected Patients
In contrast to CRF patients, EPOGEN® therapy has not been linked to exacerbation of hypertension, seizures, and thrombotic events in HIV-infected patients.

**PRECAUTIONS**
The parenteral administration of any biologic product should be attended by appropriate precautions in case allergic or other untoward reactions occur (see CONTRAINDICATIONS). In clinical trials, while transient rashes were occasionally observed concurrently with EPOGEN® therapy, no serious allergic or anaphylactic reactions were reported (see ADVERSE REACTIONS for more information regarding allergic reactions).

The safety and efficacy of EPOGEN® therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders).

In some female patients, menses have resumed following EPOGEN® therapy; the possibility of pregnancy should be discussed and the need for contraception evaluated.

**Hematology**
Exacerbation of porphyria has been observed rarely in patients with CRF treated with EPOGEN®. However, EPOGEN® has not caused increased urinary excretion of porphyrin metabolites in normal volunteers, even in the presence of a rapid erythropoietic response. Nevertheless, EPOGEN® should be used with caution in patients with known porphyria.

In preclinical studies in dogs and rats, but not in monkeys, EPOGEN® therapy was associated with subclinical bone marrow fibrosis. Bone marrow fibrosis is a known complication of CRF in humans and may be related to secondary hyperparathyroidism or unknown factors. The incidence of bone marrow fibrosis was not increased in a study of adult patients on dialysis who were treated with EPOGEN® for 12 to 19 months, compared to the incidence of bone marrow fibrosis in a matched group of patients who had not been treated with EPOGEN®.

Hemoglobin in CRF patients should be measured twice a week; zidovudine-treated HIV-infected and cancer patients should have hemoglobin measured once a week until hemoglobin has been stabilized, and measured periodically thereafter.

**Lack or Loss of Response**
If the patient fails to respond or to maintain a response to doses within the recommended dosing range, the following etiologies should be considered and evaluated:
1. Iron deficiency: Virtually all patients will eventually require supplemental iron therapy (see IRON EVALUATION).
2. Underlying infectious, inflammatory, or malignant processes.
3. Occult blood loss.
4. Underlying hematologic diseases (ie, thalassemia, refractory anemia, or other myelodysplastic disorders).
5. Vitamin deficiencies: Folic acid or vitamin B12.
6. Hemolysis.
7. Aluminum intoxication.
8. Osteitis fibrosa cystica.
9. Pure Red Cell Aplasia (PRCA): In the absence of another etiology, the patient should be evaluated for evidence of PRCA and sera should be tested for the presence of antibodies to recombinant erythropoietins.

**Iron Evaluation**
During EPOGEN® therapy, absolute or functional iron deficiency may develop. Functional iron
deficiency, with normal ferritin levels but low transferrin saturation, is presumably due to the inability to
mobilize iron stores rapidly enough to support increased erythropoiesis. Transferrin saturation should
be at least 20% and ferritin should be at least 100 ng/mL.

Prior to and during EPOGEN® therapy, the patient’s iron status, including transferrin saturation (serum
iron divided by iron binding capacity) and serum ferritin, should be evaluated. Virtually all patients will
evendually require supplemental iron to increase or maintain transferrin saturation to levels which will
adequately support erythropoiesis stimulated by EPOGEN®. All surgery patients being treated with
EPOGEN® should receive adequate iron supplementation throughout the course of therapy in order to
support erythropoiesis and avoid depletion of iron stores.

**Drug Interaction**
No evidence of interaction of EPOGEN® with other drugs was observed in the course of clinical trials.

**Carcinogenesis, Mutagenesis, and Impairment of Fertility**
Carcinogenic potential of EPOGEN® has not been evaluated. EPOGEN® does not induce bacterial
gene mutation (Ames Test), chromosomal aberrations in mammalian cells, micronuclei in mice, or gene
mutation at the HGPRT locus. In female rats treated IV with EPOGEN®, there was a trend for slightly
increased fetal wastage at doses of 100 and 500 Units/kg.

**Pregnancy Category C**
EPOGEN® has been shown to have adverse effects in rats when given in doses 5 times the human
dose. There are no adequate and well-controlled studies in pregnant women. EPOGEN® should be
used during pregnancy only if potential benefit justifies the potential risk to the fetus.

In studies in female rats, there were decreases in body weight gain, delays in appearance of abdominal
hair, delayed eyelid opening, delayed ossification, and decreases in the number of caudal vertebrae in
the F1 fetuses of the 500 Units/kg group. In female rats treated IV, there was a trend for slightly
increased fetal wastage at doses of 100 and 500 Units/kg. EPOGEN® has not shown any adverse
effect at doses as high as 500 Units/kg in pregnant rabbits (from day 6 to 18 of gestation).

**Nursing Mothers**
Postnatal observations of the live offspring (F1 generation) of female rats treated with EPOGEN® during
gestation and lactation revealed no effect of EPOGEN® at doses of up to 500 Units/kg. There were,
however, decreases in body weight gain, delays in appearance of abdominal hair, eyelid opening, and
decreases in the number of caudal vertebrae in the F1 fetuses of the 500 Units/kg group. There were
no EPOGEN®-related effects on the F2 generation fetuses.

It is not known whether EPOGEN® is excreted in human milk. Because many drugs are excreted in
human milk, caution should be exercised when EPOGEN® is administered to a nursing woman.

**Pediatric Use**
See WARNINGS: PEDIATRIC USE.
Pediatric Patients on Dialysis: EPOGEN® is indicated in infants (1 month to 2 years), children (2 years to 12 years), and adolescents (12 years to 16 years) for the treatment of anemia associated with CRF requiring dialysis. Safety and effectiveness in pediatric patients less than 1 month old have not been established (see CLINICAL EXPERIENCE: CHRONIC RENAL FAILURE, PEDIATRIC PATIENTS ON DIALYSIS). The safety data from these studies show that there is no increased risk to pediatric CRF patients on dialysis when compared to the safety profile of EPOGEN® in adult CRF patients (see ADVERSE REACTIONS and WARNINGS). Published literature has provided supportive evidence of the safety and effectiveness of EPOGEN® in pediatric CRF patients on dialysis.

Pediatric Patients Not Requiring Dialysis: Published literature has reported the use of EPOGEN® in 133 pediatric patients with anemia associated with CRF not requiring dialysis, ages 3 months to 20 years, treated with 50 to 250 Units/kg SC or IV, QW to TIW. Dose-dependent increases in hemoglobin and hematocrit were observed with reductions in transfusion requirements.

Pediatric HIV-infected Patients: Published literature has reported the use of EPOGEN® in 20 zidovudine-treated anemic HIV-infected pediatric patients ages 8 months to 17 years, treated with 50 to 400 Units/kg SC or IV, 2 to 3 times per week. Increases in hemoglobin levels and in reticulocyte counts, and decreases in or elimination of blood transfusions were observed.

Pediatric Cancer Patients on Chemotherapy: Published literature has reported the use of EPOGEN® in approximately 64 anemic pediatric cancer patients ages 6 months to 18 years, treated with 25 to 300 Units/kg SC or IV, 3 to 7 times per week. Increases in hemoglobin and decreases in transfusion requirements were noted.

Geriatric Use

Among 1051 patients enrolled in the 5 clinical trials of EPOGEN® for reduction of allogeneic blood transfusions in patients undergoing elective surgery 745 received EPOGEN® and 306 received placebo. Of the 745 patients who received EPOGEN®, 432 (58%) were aged 65 and over, while 175 (23%) were 75 and over. No overall differences in safety or effectiveness were observed between geriatric and younger patients. The dose requirements for EPOGEN® in geriatric and younger patients within the 4 trials using the TIW schedule were similar. Insufficient numbers of patients were enrolled in the study using the weekly dosing regimen to determine whether the dosing requirements differ for this schedule.

Of the 882 patients enrolled in the 3 studies of chronic renal failure patients on dialysis, 757 received EPOGEN® and 125 received placebo. Of the 757 patients who received EPOGEN®, 361 (47%) were aged 65 and over, while 100 (13%) were 75 and over. No differences in safety or effectiveness were observed between geriatric and younger patients. Dose selection and adjustment for an elderly patient should be individualized to achieve and maintain the target hematocrit (See DOSAGE AND ADMINISTRATION).

Insufficient numbers of patients age 65 or older were enrolled in clinical studies of EPOGEN® for the treatment of anemia associated with pre-dialysis chronic renal failure, cancer chemotherapy, and Zidovudine-treatment of HIV infection to determine whether they respond differently from younger subjects.

Chronic Renal Failure Patients

Patients with CRF Not Requiring Dialysis

Blood pressure and hemoglobin should be monitored no less frequently than for patients maintained on dialysis. Renal function and fluid and electrolyte balance should be closely monitored, as an improved sense of well-being may obscure the need to initiate dialysis in some patients.
Hematology
Sufficient time should be allowed to determine a patient's responsiveness to a dosage of EPOGEN® before adjusting the dose. Because of the time required for erythropoiesis and the red cell half-life, an interval of 2 to 6 weeks may occur between the time of a dose adjustment (initiation, increase, decrease, or discontinuation) and a significant change in hemoglobin.

In order to avoid reaching the suggested target hemoglobin too rapidly, or exceeding the suggested target range (hemoglobin of 10 g/dL to 12 g/dL), the guidelines for dose and frequency of dose adjustments (see DOSAGE AND ADMINISTRATION) should be followed.

For patients who respond to EPOGEN® with a rapid increase in hemoglobin (eg, more than 1 g/dL in any 2-week period), the dose of EPOGEN® should be reduced because of the possible association of excessive rate of rise of hemoglobin with an exacerbation of hypertension.

The elevated bleeding time characteristic of CRF decreases toward normal after correction of anemia in adult patients treated with EPOGEN®. Reduction of bleeding time also occurs after correction of anemia by transfusion.

Laboratory Monitoring
The hemoglobin should be determined twice a week until it has stabilized in the suggested target range and the maintenance dose has been established. After any dose adjustment, the hemoglobin should also be determined twice weekly for at least 2 to 6 weeks until it has been determined that the hemoglobin has stabilized in response to the dose change. The hemoglobin should then be monitored at regular intervals.

A complete blood count with differential and platelet count should be performed regularly. During clinical trials, modest increases were seen in platelets and white blood cell counts. While these changes were statistically significant, they were not clinically significant and the values remained within normal ranges.

In patients with CRF, serum chemistry values (including blood urea nitrogen [BUN], uric acid, creatinine, phosphorus, and potassium) should be monitored regularly. During clinical trials in adult patients on dialysis, modest increases were seen in BUN, creatinine, phosphorus, and potassium. In some adult patients with CRF not on dialysis treated with EPOGEN®, modest increases in serum uric acid and phosphorus were observed. While changes were statistically significant, the values remained within the ranges normally seen in patients with CRF.

Diet
As the hemoglobin increases and patients experience an improved sense of well-being and quality of life, the importance of compliance with dietary and dialysis prescriptions should be reinforced. In particular, hyperkalemia is not uncommon in patients with CRF. In US studies in patients on dialysis, hyperkalemia has occurred at an annualized rate of approximately 0.11 episodes per patient-year of EPOGEN® therapy, often in association with poor compliance to medication, diet, and/or dialysis.

Dialysis Management
Therapy with EPOGEN® results in an increase in hematocrit and a decrease in plasma volume which could affect dialysis efficiency. In studies to date, the resulting increase in hematocrit did not appear to adversely affect dialyzer function or the efficiency of high flux hemodialysis. During hemodialysis, patients treated with EPOGEN® may require increased anticoagulation with heparin to prevent clotting of the artificial kidney.
Patients who are marginally dialyzed may require adjustments in their dialysis prescription. As with all patients on dialysis, the serum chemistry values (including BUN, creatinine, phosphorus, and potassium) in patients treated with EPOGEN® should be monitored regularly to assure the adequacy of the dialysis prescription.

Information for Patients
In those situations in which the physician determines that a home dialysis patient can safely and effectively self-administer EPOGEN®, the patient should be instructed as to the proper dosage and administration. Home dialysis patients should be referred to the full "Information for Home Dialysis Patients" insert; it is not a disclosure of all possible effects. Patients should be informed of the signs and symptoms of an allergic drug reaction and advised of appropriate actions. If home use is prescribed for a home dialysis patient, the patient should be thoroughly instructed in the importance of proper disposal and cautioned against the reuse of needles, syringes, or drug product. A puncture-resistant container for the disposal of used syringes and needles should be available to the patient. The full container should be disposed of according to the directions provided by the physician.

Renal Function
In adult patients with CRF not on dialysis, renal function and fluid and electrolyte balance should be closely monitored, as an improved sense of well-being may obscure the need to initiate dialysis in some patients. In patients with CRF not on dialysis, placebo-controlled studies of progression of renal dysfunction over periods of greater than 1 year have not been completed. In shorter term trials in adult patients with CRF not on dialysis, changes in creatinine and creatinine clearance were not significantly different in patients treated with EPOGEN® compared with placebo-treated patients. Analysis of the slope of 1/serum creatinine versus time plots in these patients indicates no significant change in the slope after the initiation of EPOGEN® therapy.

Zidovudine-treated HIV-infected Patients
Hypertension
Exacerbation of hypertension has not been observed in zidovudine-treated HIV-infected patients treated with EPOGEN®. However, EPOGEN® should be withheld in these patients if pre-existing hypertension is uncontrolled, and should not be started until blood pressure is controlled. In double-blind studies, a single seizure has been experienced by a patient treated with EPOGEN®.

Cancer Patients on Chemotherapy
Hypertension
Hypertension, associated with a significant increase in hemoglobin, has been noted rarely in patients treated with EPOGEN®. Nevertheless, blood pressure in patients treated with EPOGEN® should be monitored carefully, particularly in patients with an underlying history of hypertension or cardiovascular disease.

Seizures
In double-blind, placebo-controlled trials, 3.2% (n = 2/63) of patients treated with EPOGEN® TIW and 2.9% (n = 2/68) of placebo-treated patients had seizures. Seizures in 1.6% (n = 1/63) of patients treated with EPOGEN® TIW occurred in the context of a significant increase in blood pressure and hematocrit from baseline values. However, both patients treated with EPOGEN® also had underlying CNS pathology which may have been related to seizure activity.
In a placebo-controlled, double-blind trial utilizing weekly dosing with EPOGEN®, 1.2% (n = 2/168) of safety-evaluable patients treated with EPOGEN® and 1% (n = 1/165) of placebo-treated patients had seizures. Seizures in the patients treated with weekly EPOGEN® occurred in the context of a significant increase in hemoglobin from baseline values however significant increases in blood pressure were not seen. These patients may have had other CNS pathology.

**Thrombotic Events**

In double-blind, placebo-controlled trials, 3.2% (n = 2/63) of patients treated with EPOGEN®, TIW and 11.8% (n = 8/68) of placebo-treated patients had thrombotic events (eg, pulmonary embolism, cerebrovascular accident), (See WARNINGS; Thrombotic Events and Increased Mortality).

In a placebo-controlled, double-blind trial utilizing weekly dosing with EPOGEN®, 6.0% (n = 10/168) of safety-evaluable patients treated with EPOGEN® and 3.6% (n = 6/165) (p = 0.444) of placebo-treated patients had clinically significant thrombotic events (deep vein thrombosis requiring anticoagulant therapy, embolic event including pulmonary embolism, myocardial infarction, cerebral ischemia, left ventricular failure and thrombotic microangiopathy). A definitive relationship between the rate of hemoglobin increase and the occurrence of clinically significant thrombotic events could not be evaluated due to the limited schedule of hemoglobin measurements in this study.

**Tumor Growth Factor Potential**

EPOGEN® is a growth factor that primarily stimulates red cell production. Erythropoietin receptors are also found to be present on the surface of some malignant cell lines and tumor biopsy specimens. However, it is not known if these receptors are functional. A randomized, placebo-controlled trial was conducted in 224 chemotherapy-naïve, non-anemic patients with small cell lung cancer receiving cisplatin-based combination chemotherapy, to investigate whether the concurrent use of EPOGEN® stimulated tumor growth as assessed by impact on overall response rate. Patients were randomized to receive EPOGEN® 150 Units/kg or placebo subcutaneously TIW during chemotherapy. The overall response rates, after 3 cycles of treatment, were 72% and 67%, in the EPOGEN® and placebo arms, respectively. Complete response rates (17% vs. 14%) and median overall survival (10.5 mos vs. 10.4 mos) were similar in the EPOGEN® and placebo arms.25

Two additional studies explored effect on survival and/or progression of administrations of other exogenous erythropoietin with higher hemoglobin targets.

In a randomized, placebo-controlled study using another Epoetin alfa product, conducted in 939 women with metastatic breast cancer, study drug dosing was titrated to attempt to maintain hemoglobin levels between 12 and 14 g/dL. At four months, death attributed to disease progression was higher (6% vs 3%) in women receiving Epoetin alfa. Overall mortality was significantly higher at 12 months in the Epoetin alfa arm (See WARNINGS; Thrombotic Events and Increased Mortality).

In a randomized, placebo-controlled study using Epoetin beta, conducted in 351 patients with head and neck cancer, study drug was administered with the aim of achieving a hemoglobin level of 14 g/dL in women and 15 g/dL in men. Locoregional progression-free survival was significantly shorter (median PFS: 406 days Epoetin beta vs 745 days placebo, p = 0.04) in patients receiving Epoetin beta.43

There is insufficient information to establish whether use of Epoetin products, including EPOGEN®, have an adverse effect on time to tumor progression or progression-free survival.
These trials permitted or required dosing to achieve hemoglobin of greater than 12 g/dL. Until further information is available, the recommended target hemoglobin should not exceed 12 g/dL in men or women.

**Surgery Patients**

**Thrombotic/Vascular Events**
In perioperative clinical trials with orthopedic patients, the overall incidence of thrombotic/vascular events was similar in Epoetin alfa and placebo-treated patients who had a pretreatment hemoglobin of > 10 g/dL to ≤ 13 g/dL. In patients with a hemoglobin of > 13 g/dL treated with 300 Units/kg of Epoetin alfa, the possibility that EPOGEN® treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded.18-20,28

In one study in which Epoetin alfa was administered in the perioperative period to patients undergoing coronary artery bypass graft surgery, there were 7 deaths in the group treated with Epoetin alfa (n = 126) and no deaths in the placebo-treated group (n = 56). Among the 7 deaths in the patients treated with Epoetin alfa, 4 were at the time of therapy (between study day 2 and 8). The 4 deaths at the time of therapy (3%) were associated with thrombotic/vascular events: A causative role of Epoetin alfa cannot be excluded (see WARNINGS).

**Hypertension**
Blood pressure may rise in the perioperative period in patients being treated with EPOGEN®. Therefore, blood pressure should be monitored carefully.

**ADVERSE REACTIONS**

**Immunogenicity**
As with all therapeutic proteins, there is the potential for immunogenicity. The observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to EPOGEN® with the incidence of antibodies to other products may be misleading.

A few cases of PRCA associated with antibodies with neutralizing activity have been reported in patients receiving EPOGEN® (see WARNINGS: PURE RED CELL APLASIA). These cases were observed in patients treated by either SC or IV routes of administration and occurred predominantly in CRF patients.

**Chronic Renal Failure Patients**
EPOGEN® is generally well-tolerated. The adverse events reported are frequent sequela of CRF and are not necessarily attributable to EPOGEN® therapy. In double-blind, placebo-controlled studies involving over 300 patients with CRF, the events reported in greater than 5% of patients treated with EPOGEN® during the blinded phase were:

<table>
<thead>
<tr>
<th>Percent of Patients Reporting Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients Treated With</strong></td>
</tr>
<tr>
<td>EPOGEN® (n = 200)</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Condition</td>
</tr>
<tr>
<td>--------------------</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Arthralgias</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Edema</td>
</tr>
<tr>
<td>Fatigue</td>
</tr>
<tr>
<td>Diarrhea</td>
</tr>
<tr>
<td>Vomiting</td>
</tr>
<tr>
<td>Chest Pain</td>
</tr>
<tr>
<td>Skin Reaction</td>
</tr>
<tr>
<td>(Administration Site)</td>
</tr>
<tr>
<td>Asthenia</td>
</tr>
<tr>
<td>Dizziness</td>
</tr>
<tr>
<td>Clotted Access</td>
</tr>
</tbody>
</table>

Significant adverse events of concern in patients with CRF treated in double-blind, placebo-controlled trials occurred in the following percent of patients during the blinded phase of the studies:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Incidence</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure</td>
<td>1.1%</td>
<td>1.1%</td>
</tr>
<tr>
<td>CVA/TIA</td>
<td>0.4%</td>
<td>0.6%</td>
</tr>
<tr>
<td>MI</td>
<td>0.4%</td>
<td>1.1%</td>
</tr>
<tr>
<td>Death</td>
<td>0%</td>
<td>1.7%</td>
</tr>
</tbody>
</table>

In the US EPOGEN® studies in adult patients on dialysis (over 567 patients), the incidence (number of events per patient-year) of the most frequently reported adverse events were: hypertension (0.75), headache (0.40), tachycardia (0.31), nausea/vomiting (0.26), clotted vascular access (0.25), shortness of breath (0.14), hyperkalemia (0.11), and diarrhea (0.11). Other reported events occurred at a rate of less than 0.10 events per patient per year.

Events reported to have occurred within several hours of administration of EPOGEN® were rare, mild, and transient, and included injection site stinging in dialysis patients and flu-like symptoms such as arthralgias and myalgias.

In all studies analyzed to date, EPOGEN® administration was generally well-tolerated, irrespective of the route of administration.

*Pediatric CRF Patients:* In pediatric patients with CRF on dialysis, the pattern of most adverse events was similar to that found in adults. Additional adverse events reported during the double-blind phase in >10% of pediatric patients in either treatment group were: abdominal pain, dialysis access complications including access infections and peritonitis in those receiving peritoneal dialysis, fever, upper respiratory infection, cough, pharyngitis, and constipation. The rates are similar between the treatment groups for each event.
**Hypertension:** Increases in blood pressure have been reported in clinical trials, often during the first 90 days of therapy. On occasion, hypertensive encephalopathy and seizures have been observed in patients with CRF treated with EPOGEN®. When data from all patients in the US phase 3 multicenter trial were analyzed, there was an apparent trend of more reports of hypertensive adverse events in patients on dialysis with a faster rate of rise of hematocrit (greater than 4 hematocrit points in any 2-week period). However, in a double-blind, placebo-controlled trial, hypertensive adverse events were not reported at an increased rate in the group treated with EPOGEN® (150 Units/kg TIW) relative to the placebo group.

**Seizures:** There have been 47 seizures in 1010 patients on dialysis treated with EPOGEN® in clinical trials, with an exposure of 986 patient-years for a rate of approximately 0.048 events per patient-year. However, there appeared to be a higher rate of seizures during the first 90 days of therapy (occurring in approximately 2.5% of patients) when compared to subsequent 90-day periods. The baseline incidence of seizures in the untreated dialysis population is difficult to determine; it appears to be in the range of 5% to 10% per patient-year.39-41

**Thrombotic Events:** In clinical trials where the maintenance hematocrit was 35 ± 3% on EPOGEN®, clotting of the vascular access (A-V shunt) has occurred at an annualized rate of about 0.25 events per patient-year, and other thrombotic events (eg, myocardial infarction, cerebral vascular accident, transient ischemic attack, and pulmonary embolism) occurred at a rate of 0.04 events per patient-year. In a separate study of 1111 untreated dialysis patients, clotting of the vascular access occurred at a rate of 0.50 events per patient-year. However, in CRF patients on hemodialysis who also had clinically evident ischemic heart disease or congestive heart failure, the risk of A-V shunt thrombosis was higher (39% vs 29%, p < 0.001), and myocardial infarctions, vascular ischemic events, and venous thrombosis were increased, in patients targeted to a hematocrit of 42 ± 3% compared to those maintained at 30 ± 3% (see WARNINGS).

In patients treated with commercial EPOGEN®, there have been rare reports of serious or unusual thrombo-embolic events including migratory thrombophlebitis, microvascular thrombosis, pulmonary embolus, and thrombosis of the retinal artery, and temporal and renal veins. A causal relationship has not been established.

**Allergic Reactions:** There have been no reports of serious allergic reactions or anaphylaxis associated with EPOGEN® administration during clinical trials. Skin rashes and urticaria have been observed rarely and when reported have generally been mild and transient in nature.

There have been rare reports of potentially serious allergic reactions including urticaria with associated respiratory symptoms or circumoral edema, or urticaria alone. Most reactions occurred in situations where a causal relationship could not be established. Symptoms recurred with rechallenge in a few instances, suggesting that allergic reactivity may occasionally be associated with EPOGEN® therapy. If an anaphylactoid reaction occurs, EPOGEN® should be immediately discontinued and appropriate therapy initiated.

**Zidovudine-treated HIV-Infected Patients**
Adverse events reported in clinical trials with EPOGEN® in zidovudine-treated HIV-infected patients were consistent with the progression of HIV infection. In double-blind, placebo-controlled studies of 3 months duration involving approximately 300 zidovudine-treated HIV-infected patients, adverse events with an incidence of ≥ 10% in either patients treated with EPOGEN® or placebo-treated patients were:

<table>
<thead>
<tr>
<th>Percent of Patients Reporting Event</th>
<th>Patients Treated With</th>
<th>Placebo-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Event</th>
<th>EPOGEN(^\circledast) (n = 144)</th>
<th>Patients (n = 153)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrexia</td>
<td>38%</td>
<td>29%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>25%</td>
<td>31%</td>
</tr>
<tr>
<td>Headache</td>
<td>19%</td>
<td>14%</td>
</tr>
<tr>
<td>Cough</td>
<td>18%</td>
<td>14%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>16%</td>
<td>18%</td>
</tr>
<tr>
<td>Rash</td>
<td>16%</td>
<td>8%</td>
</tr>
<tr>
<td>Congestion, Respiratory</td>
<td>15%</td>
<td>10%</td>
</tr>
<tr>
<td>Nausea</td>
<td>15%</td>
<td>12%</td>
</tr>
<tr>
<td>Shortness of Breath</td>
<td>14%</td>
<td>13%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>11%</td>
<td>14%</td>
</tr>
<tr>
<td>Skin Reaction, Medication Site</td>
<td>10%</td>
<td>7%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>9%</td>
<td>10%</td>
</tr>
</tbody>
</table>

In the 297 patients studied, EPOGEN\(^\circledast\) was not associated with significant increases in opportunistic infections or mortality.\(^{25}\) In 71 patients from this group treated with EPOGEN\(^\circledast\) at 150 Units/kg TIW, serum p24 antigen levels did not appear to increase.\(^{27}\) Preliminary data showed no enhancement of HIV replication in infected cell lines in vitro.\(^{25}\)

Peripheral white blood cell and platelet counts are unchanged following EPOGEN\(^\circledast\) therapy.

**Allergic Reactions:** Two zidovudine-treated HIV-infected patients had urticarial reactions within 48 hours of their first exposure to study medication. One patient was treated with EPOGEN\(^\circledast\) and one was treated with placebo (EPOGEN vehicle alone). Both patients had positive immediate skin tests against their study medication with a negative saline control. The basis for this apparent pre-existing hypersensitivity to components of the EPOGEN\(^\circledast\) formulation is unknown, but may be related to HIV-induced immunosuppression or prior exposure to blood products.

**Seizures:** In double-blind and open-label trials of EPOGEN\(^\circledast\) in zidovudine-treated HIV-infected patients, 10 patients have experienced seizures.\(^{25}\) In general, these seizures appear to be related to underlying pathology such as meningitis or cerebral neoplasms, not EPOGEN\(^\circledast\) therapy.

**Cancer Patients on Chemotherapy**
Adverse experiences reported in clinical trials with EPOGEN\(^\circledast\) administered TIW in cancer patients were consistent with the underlying disease state. In double-blind, placebo-controlled studies of up to 3 months duration involving 131 cancer patients, adverse events with an incidence > 10% in either patients treated with EPOGEN\(^\circledast\) or placebo-treated patients were as indicated below:

**Percent of Patients Reporting Event**

<table>
<thead>
<tr>
<th></th>
<th>Patients Treated With</th>
<th>Placebo-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Event</th>
<th>EPOGEN® (&lt;i&gt;n = 63&lt;/i&gt;)</th>
<th>Patients (&lt;i&gt;n = 68&lt;/i&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrexia</td>
<td>29%</td>
<td>19%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21%*</td>
<td>7%</td>
</tr>
<tr>
<td>Nausea</td>
<td>17%*</td>
<td>32%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>17%</td>
<td>15%</td>
</tr>
<tr>
<td>Edema</td>
<td>17%*</td>
<td>1%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>13%</td>
<td>16%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>13%</td>
<td>15%</td>
</tr>
<tr>
<td>Shortness of Breath</td>
<td>13%</td>
<td>9%</td>
</tr>
<tr>
<td>Parasthesia</td>
<td>11%</td>
<td>6%</td>
</tr>
<tr>
<td>Upper Respiratory</td>
<td>11%</td>
<td>4%</td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>5%</td>
<td>12%</td>
</tr>
<tr>
<td>Trunk Pain</td>
<td>3%*</td>
<td>16%</td>
</tr>
</tbody>
</table>

* Statistically significant

Although some statistically significant differences between patients being treated with EPOGEN® and placebo-treated patients were noted, the overall safety profile of EPOGEN® appeared to be consistent with the disease process of advanced cancer. During double-blind and subsequent open-label therapy in which patients (<i>n = 72</i>) were treated for up to 32 weeks with doses as high as 927 Units/kg, the adverse experience profile of EPOGEN® was consistent with the progression of advanced cancer.

Three hundred thirty-three (333) cancer patients enrolled in a placebo-controlled double-blind trial utilizing Weekly dosing with EPOGEN® for up to 4 months were evaluable for adverse events. The incidence of adverse events was similar in both the treatment and placebo arms.

**Surgery Patients**
Adverse events with an incidence of ≥ 10% are shown in the following table:

<table>
<thead>
<tr>
<th>Event</th>
<th>Patients Treated With EPOGEN®&lt;sup&gt;a&lt;/sup&gt; (n = 112)</th>
<th>Patients Treated With EPOGEN®&lt;sup&gt;a&lt;/sup&gt; (n = 101)</th>
<th>Placebo-treated Patients (n = 103)</th>
<th>Patients Treated With EPOGEN®&lt;sup&gt;b&lt;/sup&gt; 600 U/kg (n = 73)</th>
<th>Patients Treated With EPOGEN®&lt;sup&gt;b&lt;/sup&gt; 300 U/kg (n = 72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrexia</td>
<td>51%</td>
<td>50%</td>
<td>60%</td>
<td>47%</td>
<td>42%</td>
</tr>
<tr>
<td>Nausea</td>
<td>48%</td>
<td>43%</td>
<td>45%</td>
<td>45%</td>
<td>58%</td>
</tr>
<tr>
<td>Constipation</td>
<td>43%</td>
<td>42%</td>
<td>43%</td>
<td>51%</td>
<td>53%</td>
</tr>
<tr>
<td>Skin Reaction</td>
<td>25%</td>
<td>19%</td>
<td>22%</td>
<td>26%</td>
<td>29%</td>
</tr>
<tr>
<td>Medication</td>
<td>Site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Vomiting</td>
<td>22%</td>
<td>12%</td>
<td>14%</td>
<td>21%</td>
<td>29%</td>
</tr>
<tr>
<td>Skin Pain</td>
<td>18%</td>
<td>18%</td>
<td>17%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Pruritus</td>
<td>16%</td>
<td>16%</td>
<td>14%</td>
<td>14%</td>
<td>22%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>13%</td>
<td>16%</td>
<td>13%</td>
<td>21%</td>
<td>18%</td>
</tr>
<tr>
<td>Headache</td>
<td>13%</td>
<td>11%</td>
<td>9%</td>
<td>10%</td>
<td>19%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>12%</td>
<td>9%</td>
<td>12%</td>
<td>11%</td>
<td>21%</td>
</tr>
<tr>
<td>Urinary Tract</td>
<td>12%</td>
<td>3%</td>
<td>11%</td>
<td>11%</td>
<td>8%</td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>10%</td>
<td>11%</td>
<td>10%</td>
<td>5%</td>
<td>10%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10%</td>
<td>7%</td>
<td>12%</td>
<td>10%</td>
<td>6%</td>
</tr>
<tr>
<td>Deep Venous</td>
<td>10%</td>
<td>3%</td>
<td>5%</td>
<td>0%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0%&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Thrombosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>9%</td>
<td>11%</td>
<td>6%</td>
<td>7%</td>
<td>8%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>7%</td>
<td>2%</td>
<td>11%</td>
<td>11%</td>
<td>4%</td>
</tr>
<tr>
<td>Edema</td>
<td>6%</td>
<td>11%</td>
<td>8%</td>
<td>11%</td>
<td>7%</td>
</tr>
</tbody>
</table>

<sup>a</sup> Study including patients undergoing orthopedic surgery treated with EPOGEN<sup>c</sup> or placebo for 15 days

<sup>b</sup> Study including patients undergoing orthopedic surgery treated with EPOGEN<sup>c</sup> 600 Units/kg weekly × 4 or 300 Units/kg daily × 15

<sup>c</sup> Determined by clinical symptoms

**Thrombotic/Vascular Events:** In three double-blind, placebo-controlled orthopedic surgery studies, the rate of deep venous thrombosis (DVT) was similar among Epoetin alfa and placebo-treated patients in the recommended population of patients with a pretreatment hemoglobin of > 10 g/dL to ≤ 13 g/dL. However, in 2 of 3 orthopedic surgery studies the overall rate (all pretreatment hemoglobin groups combined) of DVTs detected by postoperative ultrasonography and/or surveillance venography was higher in the group treated with Epoetin alfa than in the placebo-treated group (11% vs 6%). This finding was attributable to the difference in DVT rates observed in the subgroup of patients with pretreatment hemoglobin > 13 g/dL. However, the incidence of DVTs was within the range of that reported in the literature for orthopedic surgery patients.

In the orthopedic surgery study of patients with pretreatment hemoglobin of > 10 g/dL to ≤ 13 g/dL which compared two dosing regimens (600 Units/kg weekly × 4 and 300 Units/kg daily × 15), 4 subjects in the 600 Units/kg weekly EPOGEN<sup>c</sup> group (5%) and no subjects in the 300 Units/kg daily group had a thrombotic vascular event during the study period.<sup>19</sup>

In a study examining the use of Epoetin alfa in 182 patients scheduled for coronary artery bypass graft surgery, 23% of patients treated with Epoetin alfa and 29% treated with placebo experienced thrombotic/vascular events. There were 4 deaths among the Epoetin alfa-treated patients that were associated with a thrombotic/vascular event. A causative role of Epoetin alfa cannot be excluded (see WARNINGS).
OVERDOSAGE
The maximum amount of EPOGEN® that can be safely administered in single or multiple doses has not been determined. Doses of up to 1500 Units/kg TIW for 3 to 4 weeks have been administered to adults without any direct toxic effects of EPOGEN® itself. Therapy with EPOGEN® can result in polycythemia if the hemoglobin is not carefully monitored and the dose appropriately adjusted. If the suggested target range is exceeded, EPOGEN® may be temporarily withheld until the hemoglobin returns to the suggested target range; EPOGEN® therapy may then be resumed using a lower dose (see DOSAGE AND ADMINISTRATION). If polycythemia is of concern, phlebotomy may be indicated to decrease the hemoglobin.

DOSAGE AND ADMINISTRATION
Chronic Renal Failure Patients
The recommended range for the starting dose of EPOGEN® is 50 to 100 Units/kg TIW for adult patients. The recommended starting dose for pediatric CRF patients on dialysis is 50 Units/kg TIW. The dose of EPOGEN® should be reduced as the hemoglobin approaches 12 g/dL or increases by more than 1 g/dL in any 2-week period. The dosage of EPOGEN® must be individualized to maintain the hemoglobin within the suggested target range. At the physician's discretion, the suggested target hemoglobin range may be expanded to achieve maximal patient benefit.

EPOGEN® may be given either as an IV or SC injection. In patients on hemodialysis, EPOGEN® usually has been administered as an IV bolus TIW. While the administration of EPOGEN® is independent of the dialysis procedure, EPOGEN® may be administered into the venous line at the end of the dialysis procedure to obviate the need for additional venous access. In adult patients with CRF not on dialysis, EPOGEN® may be given either as an IV or SC injection.

Patients who have been judged competent by their physicians to self-administer EPOGEN® without medical or other supervision may give themselves either an IV or SC injection. The table below provides general therapeutic guidelines for patients with CRF:

Starting Dose:
Adults
Pediatric Patients
50 to 100 Units/kg TIW; IV or SC
50 Units/kg TIW; IV or SC

Reduce Dose When:
1. Hgb approaches 12 g/dL or,
2. Hgb increases > 1 g/dL in any 2-week period

Increase Dose If:
Hgb does not increase by 2 g/dL after 8 weeks of therapy, and hgb is below suggested target range

Maintenance Dose:
Individually titrate

Suggested Target Hgb Range:
10 g/dL to 12 g/dL

During therapy, hematological parameters should be monitored regularly (see LABORATORY MONITORING).
Pretherapy Iron Evaluation: Prior to and during EPOGEN® therapy, the patient's iron stores, including transferrin saturation (serum iron divided by iron binding capacity) and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will eventually require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis stimulated by EPOGEN®.

Dose Adjustment: The dose should be adjusted for each patient to achieve and maintain a target hemoglobin not to exceed 12 g/dL.

Increases in dose should not be made more frequently than once a month. If the hemoglobin is increasing and approaching 12 g/dL, the dose should be reduced by approximately 25%. If the hemoglobin continues to increase, dose should be temporarily withheld until the hemoglobin begins to decrease, at which point therapy should be reinitiated at a dose approximately 25% below the previous dose. If the hemoglobin increases by more than 1 g/dL in a 2-week period, the dose should be decreased by approximately 25%.

If the increase in the hemoglobin is less than 1 g/dL over 4 weeks and iron stores are adequate (see PRECAUTIONS: Laboratory Monitoring), the dose of EPOGEN® may be increased by approximately 25% of the previous dose. Further increases may be made at 4-week intervals until the specified hemoglobin is obtained.

Maintenance Dose: The maintenance dose must be individualized for each patient on dialysis. In the US phase 3 multicenter trial in patients on hemodialysis, the median maintenance dose was 75 Units/kg TIW, with a range from 12.5 to 525 Units/kg TIW. Almost 10% of the patients required a dose of 25 Units/kg, or less, and approximately 10% of the patients required more than 200 Units/kg TIW to maintain their hematocrit in the suggested target range. In pediatric hemodialysis and peritoneal dialysis patients, the median maintenance dose was 167 Units/kg/week (49 to 447 Units/kg per week) and 76 Units/kg per week (24 to 323 Units/kg/week) administered in divided doses (TIW or BIW), respectively to achieve the target range of 30% to 36%.

If the hemoglobin remains below, or falls below, the suggested target range, iron stores should be re-evaluated. If the transferrin saturation is less than 20%, supplemental iron should be administered. If the transferrin saturation is greater than 20%, the dose of EPOGEN® may be increased. Such dose increases should not be made more frequently than once a month, unless clinically indicated, as the response time of the hemoglobin to a dose increase can be 2 to 6 weeks. Hemoglobin should be measured twice weekly for 2 to 6 weeks following dose increases. In adult patients with CRF not on dialysis, the maintenance dose must also be individualized. EPOGEN® doses of 75 to 150 Units/kg/week have been shown to maintain hematocrits of 36% to 38% for up to 6 months.

Lack or Loss of Response: Over 95% of patients with CRF responded with clinically significant increases in hematocrit, and virtually all patients were transfusion-independent within approximately 2 months of initiation of EPOGEN® therapy.

If a patient fails to respond or maintain a response, other etiologies should be considered and evaluated as clinically indicated (see PRECAUTIONS: LACK OR LOSS OF RESPONSE).

Zidovudine-treated HIV-infected Patients
Prior to beginning EPOGEN®, it is recommended that the endogenous serum erythropoietin level be determined (prior to transfusion). Available evidence suggests that patients receiving zidovudine with endogenous serum erythropoietin levels > 500 mUnits/mL are unlikely to respond to therapy with EPOGEN®.
**Starting Dose:** For adult patients with serum erythropoietin levels ≤ 500 mUnits/mL who are receiving a dose of zidovudine ≤ 4200 mg/week, the recommended starting dose of EPOGEN® is 100 Units/kg as an IV or SC injection TIW for 8 weeks. For pediatric patients, see PRECAUTIONS: PEDIATRIC USE.

**Increase Dose:** During the dose adjustment phase of therapy, the hemoglobin should be monitored weekly. If the response is not satisfactory in terms of reducing transfusion requirements or increasing hemoglobin after 8 weeks of therapy, the dose of EPOGEN® can be increased by 50 to 100 Units/kg TIW. Response should be evaluated every 4 to 8 weeks thereafter and the dose adjusted accordingly by 50 to 100 Units/kg increments TIW. If patients have not responded satisfactorily to an EPOGEN® dose of 300 Units/kg TIW, it is unlikely that they will respond to higher doses of EPOGEN®.

**Maintenance Dose:** After attainment of the desired response (ie, reduced transfusion requirements or increased hemoglobin), the dose of EPOGEN® should be titrated to maintain the response based on factors such as variations in zidovudine dose and the presence of intercurrent infectious or inflammatory episodes. If the hemoglobin exceeds 13 g/dL, the dose should be discontinued until the hemoglobin drops to 12 g/dL. The dose should be reduced by 25% when treatment is resumed and then titrated to maintain the desired hemoglobin.

**Cancer Patients on Chemotherapy**
Although no specific serum erythropoietin level can be stipulated above which patients would be unlikely to respond to EPOGEN® therapy, treatment of patients with grossly elevated serum erythropoietin levels (eg, > 200 mUnits/mL) is not recommended. The hemoglobin should be monitored on a weekly basis in patients receiving EPOGEN® therapy until hemoglobin becomes stable. The dose of EPOGEN® should be titrated to maintain the desired hemoglobin.

Two EPOGEN® dosing regimens may be used in adults; 150 Units/kg SC TIW or 40,000 Units SC Weekly. For pediatric patients, see PRECAUTIONS: PEDIATRIC USE.

**TIW Dosing**

**Starting Dose:**
- **Adults:** 150 Units/kg SC TIW
- **Pediatric Patients:** See PRECAUTIONS: Pediatric Use

**Reduce Dose by 25% when:**
1. Hgb approaches 12 g/dL or,
2. Hgb increases > 1 g/dL in any 2-week period

**Withhold Dose if:**
Hgb exceeds 13 g/dL, until the hemoglobin falls to 12 g/dL, and restart dose at 25% below the previous dose

**Increase Dose to 300 Units/kg TIW if:** response is not satisfactory [no reduction in transfusion requirements or rise in hemoglobin] after 8 weeks

**Suggested Target Hgb Range:** 10 g/dL to 12 g/dL

During therapy, hematological parameters should be monitored regularly (see PRECAUTIONS: Laboratory Monitoring).

**Weekly Dosing**
- The starting dose in adults is 40,000 Units SC Weekly. If after 4 weeks of therapy, the hemoglobin has not increased by ≥ 1 g/dL, in the absence of RBC transfusion, the EPOGEN® dose should be increased to 60,000 Units Weekly.
• If patients have not responded satisfactorily to an EPOGEN® dose of 60,000 Units Weekly after 4 weeks, it is unlikely that they will respond to higher doses of EPOGEN®.
• EPOGEN® should be withheld if the hemoglobin exceeds 13 g/dL and reinitiated with a 25% dose reduction when the hemoglobin is less than 12 g/dL.
• If EPOGEN® treatment produces a very rapid hemoglobin response (e.g., an increase of more than 1 g/dL in any 2-week period), the dose of EPOGEN® should be reduced by 25%.

Surgery Patients
Prior to initiating treatment with EPOGEN®, a hemoglobin should be obtained to establish that it is >10 to ≤13 g/dL. The recommended dose of EPOGEN® is 300 Units/kg/day subcutaneously for 10 days before surgery, on the day of surgery, and for 4 days after surgery.

An alternate dose schedule is 600 Units/kg EPOGEN® subcutaneously in once weekly doses (21, 14, and 7 days before surgery) plus a fourth dose on the day of surgery.

All patients should receive adequate iron supplementation. Iron supplementation should be initiated no later than the beginning of treatment with EPOGEN® and should continue throughout the course of therapy.

PREPARATION AND ADMINISTRATION OF EPOGEN®
1. Do not shake. It is not necessary to shake EPOGEN®. Prolonged vigorous shaking may denature any glycoprotein, rendering it biologically inactive.

2. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any vials exhibiting particulate matter or discoloration.

3. Using aseptic techniques, attach a sterile needle to a sterile syringe. Remove the flip top from the vial containing EPOGEN®, and wipe the septum with a disinfectant. Insert the needle into the vial, and withdraw into the syringe an appropriate volume of solution.

4. Single-dose: 1 mL vial contains no preservative. Use one dose per vial; do not re-enter the vial. Discard unused portions.

      Multidose: 1 mL and 2 mL vials contain preservative. Store at 2° to 8° C after initial entry and between doses. Discard 21 days after initial entry.

5. Do not dilute or administer in conjunction with other drug solutions. However, at the time of SC administration, preservative-free EPOGEN® from single-use vials may be admixed in a syringe with bacteriostatic 0.9% sodium chloride injection, USP, with benzyl alcohol 0.9% (bacteriostatic saline) at a 1:1 ratio using aseptic technique. The benzyl alcohol in the bacteriostatic saline acts as a local anesthetic which may ameliorate SC injection site discomfort. Admixing is not necessary when using the multidose vials of EPOGEN® containing benzyl alcohol.

HOW SUPPLIED
EPOGEN®, containing Epoetin alfa, is available in the following packages:

1 mL Single-dose, Preservative-free Solution
   2000 Units/mL (NDC 55513-126-10)
   3000 Units/mL (NDC 55513-267-10)
   4000 Units/mL (NDC 55513-148-10)
   10,000 Units/mL (NDC 55513-144-10)
40,000 Units/mL (NDC 55513-823-10)
Supplied in dispensing packs containing 10 single-dose vials.

2 mL Multidose, Preserved Solution
10,000 Units/mL (NDC 55513-283-10)

1 mL Multidose, Preserved Solution
20,000 Units/mL (NDC 55513-478-10)
Supplied in dispensing packs containing 10 multidose vials.

STORAGE
Store at 2° to 8 °C (36° to 46 °F). Do not freeze or shake.

REFERENCES


42. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. NEJM. 1998;339:584-90.


This product's label may have been revised after this insert was used in production. For further product information and the current package insert, please visit www.amgen.com or call our medical information department toll-free at 1-800-77AMGEN (1-800-772-6436).

Manufactured by:
Amgen Manufacturing, Limited,
a subsidiary of Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
CLINICAL PHARMACOLOGY REVIEW

Date: October 26, 2004

From: Anil K. Rajpal, M.D., Clinical Pharmacology Reviewer

Through: Martin D. Green, Ph.D., Associate Director for Pharmacology and Toxicology, ODE VI

and

Through: Patricia Keegan, M.D., Director, Division of Therapeutic Biologic Oncology Products, ODE VI

Subject: Clinical Pharmacology Review of Biologic License Application STN 103234/5076 for Epoetin alfa from Amgen.

To: Office / Division – ODE VI / Division of Therapeutic Biologic Oncology Products

Please see the attached review.
TABLE OF CONTENTS

TABLE OF CONTENTS .................................................................................................................. 1
BACKGROUND .............................................................................................................................. 2
SYNOPSIS ...................................................................................................................................... 3
   Kling et al Study ............................................................................................................................ 3
      Case Report ............................................................................................................................... 3
      Comparison with PK in Adults .................................................................................................. 5
   PK Results in Another Infant ..................................................................................................... 6
   Authors' Conclusions .................................................................................................................. 6
   Reviewer's Comments ................................................................................................................ 7
   Widness et al Study .................................................................................................................... 8
      Study Methods and Results ...................................................................................................... 8
      Authors' Conclusions ................................................................................................................. 12
      Reviewer's Comments .............................................................................................................. 13
RECOMMENDATIONS .................................................................................................................. 14
COMMENTS TO THE SPONSOR .................................................................................................. 15
Appendix 1 ...................................................................................................................................... 16
Appendix 2 ...................................................................................................................................... 17
BACKGROUND

The sponsor has submitted a Past Approval Supplement (PAS) to fulfill the following post-marketing commitment (PMC) agreed to on May 11, 1999 for Epoetin alfa license 103234: "...to complete your literature search to find additional references to support the pharmacokinetic profile of Epoetin alfa in neonates. We agree that you should include any relevant articles resulting from this search in the Package insert at the next revision, and submit a supplement."

The current Pharmacokinetics section of the Package Insert states the following:

The pharmacokinetic profile of epoetin alfa in children and adolescents appears to be similar to that of adults. Limited data are available in neonates.\(^7\)

Reference 17 in the label is a case report by Kling et al of an infant with anemia and chronic renal failure who was treated with recombinant human erythropoietin from 1 to 4 months of age.

The sponsor states that a literature search yielded an article by Widness et al. The Widness et al article describes the results of erythropoietin pharmacokinetic studies in seven premature infants and ten normal adults at escalating rhEPO doses (10, 100, and 500 IU/kg). The sponsor states that the Agency replied that it is unlikely that the Widness et al article would be acceptable because premature and full term neonates are not the same. The sponsor states that to the best of the sponsor’s knowledge, the commitment has been fulfilled, and requests that the status of the post-marketing commitment be changed to completed.

<table>
<thead>
<tr>
<th>Overview of Reference Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Kling et al</td>
</tr>
<tr>
<td>Widness et al</td>
</tr>
</tbody>
</table>

* The first subject had a history of anemia and chronic renal failure. PK values for a second infant with renal failure were added to the article as a footnote. Gestational age at birth of second infant not provided. Second infant was 29 days old when treated, and weighed 2.86 kg.
# 7 premature infants and 10 healthy adult volunteers were studied.
† Age at treatment was 7-28 days (if born at 28 to 30 wk gestation), 7-35 days (if born at 27 wk gestation), and 7-42 days (if born at < 27 wk gestation).
SYNOPSIS

**Kling et al Study**


The article is a case report of an infant with anemia and chronic renal failure who was treated with recombinant human erythropoietin (300 to 750 IU/kg SC per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. PK studies were performed after IV doses.

The author compares PK after IV doses in the case report infant with PK in 16 healthy adults after IV doses (results in adults obtained from an article by Flaharty et al).

The author also reports PK in an additional infant with renal failure caused by posterior urethral valves.

**Case Report**

**Case History:**

A 2560 gram white male infant was born at 36 weeks of gestation with a fetal diagnosis of bladder neck obstruction; he was treated prenatally with a percutaneous double-pigtail bladder shunt. Postnatal studies demonstrated urethral valves, hydronephrosis, bilateral cystic kidneys, and severe bilateral vesicoureteral reflux; renal scan showed no localization of the radioisotope in either kidney.

Because of persistent anemia (hemoglobin level 82 gm/L), reticulocytopenia (absolute count 33 X 10^9 cells/L), and a low serum Ep level (11.7 mU/ml), rhEp therapy (100 U/kg SC three times a week) was begun at 31 days of age. Oral ferrous sulfate supplementation (6 mg elemental iron per kg daily) was also started. The rhEp dose was increased to 175 U/kg (525 U/kg per week) at day 46. At day 52, a transfusion was given when the hemoglobin concentration was 66 gm/L. (posttransfusion hemoglobin level, 126 gm/L). After transfusion, hypertension developed and was treated with antihypertensive therapy. At day 86, rhEp was withheld for 10 days; there was no change in BP, and hemoglobin concentrations decreased to a nadir of 90 gm/dL. Administration of rhEp was re-instituted at 250 U/kg (750 U/kg per week). At day 104, a peritoneal dialysis catheter was placed.

**Methods:**

Product administered: Recombinant human erythropoietin.

No further product information is provided. Amgen stated in a reply to FDA question about the product used that the source of epoetin alfa used is "to the best of our knowledge, Epogen/Procrit."
Dosing summary:

<table>
<thead>
<tr>
<th>Age (days)</th>
<th>Dose of rhEp</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 - 45</td>
<td>100 U/kg SC T.I.W.</td>
</tr>
<tr>
<td>46 - 85</td>
<td>175 U/kg SC T.I.W.</td>
</tr>
<tr>
<td>86 - 95</td>
<td>--</td>
</tr>
<tr>
<td>96 – 116</td>
<td>250 U/kg SC T.I.W.</td>
</tr>
</tbody>
</table>

A pharmacokinetic study at 31 days was performed after rhEp 100 U/kg IV. A pharmacokinetic study at 102 days was performed after rhEp 250 U/kg IV.

**Pharmacokinetics:** rhEp pharmacokinetic studies were performed at 31 and 102 days. The pharmacokinetic study at 31 days was performed after rhEp 100 U/kg IV; the pharmacokinetic study at 102 days was performed after rhEp 250 U/kg IV. Heel-stick blood samples were obtained before and at 15 and 30 minutes and at 1, 1½, 2½, 4, 6, 7, and 44 hours after rapid intravenous rhEp infusion. Serum Ep was measured by radioimmunoassay.

**Pharmacodynamics:** Marrow aspirates were obtained on days 31, 82, and 104. Hematologic studies, serum iron indexes, and bone marrow histopathological examinations were done in the clinical laboratories. Low-density marrow mononuclear cells obtained by density gradient centrifugation were cultured in plasma clot and methylcellulose colony assays. Early and late progenitor cells were counted in quadruplicate after 10 to 12 and 5 to 7 days of incubation, respectively.

**Results:**

**Pharmacokinetics:** The serum Ep pharmacokinetic parameters were obtained by a least squares bi-exponential fit of the rhEp plasma concentration versus time data. rhEp concentration versus time curve is shown in Appendix 1. Pharmacokinetic parameter values are shown below. (Pharmacokinetic parameter values are taken from page 824 of the Kling et al article.)

<table>
<thead>
<tr>
<th>Pharmacokinetic studies</th>
<th>Before therapy; age 30 days</th>
<th>Dose 750 U/kg per week; age 103 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>100 U/kg IV</td>
<td>250 U/kg IV</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>2.618</td>
<td>4.100</td>
</tr>
<tr>
<td>Plasma CL (ml/kg*hr)</td>
<td>12.6</td>
<td>14.8</td>
</tr>
<tr>
<td>Volume of distribution</td>
<td>82.8</td>
<td>57.8</td>
</tr>
<tr>
<td>(ml/kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vₜₘₜ (ml/kg)</td>
<td>120</td>
<td>79.8</td>
</tr>
<tr>
<td>t₁/₂α (hr)</td>
<td>1.3</td>
<td>1.6</td>
</tr>
<tr>
<td>t₁/₂β (hr)</td>
<td>7.4</td>
<td>4.8</td>
</tr>
<tr>
<td>MRT (hr)</td>
<td>9.5</td>
<td>5.1</td>
</tr>
</tbody>
</table>

There was little difference in the t₁/₂α and clearance at 31 and 103 days.
There were decreases in the volume of distribution, $t_{1/2b}$, and MRT at 103 days relative to 31 days.

**Pharmacodynamics:**

Laboratory data at three intervals is shown below. (Laboratory data values are taken from page 824 of the Kling et al article.)

<table>
<thead>
<tr>
<th>Hematologic indexes</th>
<th>Before therapy; age 30 days</th>
<th>Dose 525 U/kg per week; age 82 days</th>
<th>Dose 750 U/kg per week; age 103 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ep (mU/mL)</td>
<td>11.7</td>
<td>31.1</td>
<td>30.3</td>
</tr>
<tr>
<td>Hemoglobin (gm/L)</td>
<td>82</td>
<td>117*</td>
<td>107</td>
</tr>
<tr>
<td>Absolute reticulocyte count ($10^5$/L)</td>
<td>33</td>
<td>24</td>
<td>85</td>
</tr>
</tbody>
</table>

**Iron indexes**

| Serum ferritin (µg/L) | 176.6                      | 97.3                              | 97.3                              |
| Serum iron (µmol/L)   | 11                         | 4                                 | 13                                |
| TIBC (µg/L)           | 46                         | 41                                | 33                                |
| Transferrin saturation (%) | 25                         | 11                                | 40                                |

**Hematopoietic progenitors**

| BFU-E (colonies 2.5 X 10^6 cells) | 141                        | 202                               | 123                               |
| CFU-E (colonies 2.5 X 10^5 cells) | 98                         | 209                               | 78                                |
| BFU-E (colonies 2.5 X 10^5 cells) | 3.5                        | 32                                | 32                                |

BFU-E, Burst-forming unit – erythroid (early progenitor); CFU-E, colony-forming unit – erythroid (late progenitor); CFU-GM, colony-forming unit – granulocyte-macrophage.

* Hemoglobin after transfusion.

Additional hemoglobin levels are stated below. These values were taken from the text of the Kling et al article.

<table>
<thead>
<tr>
<th>Hemoglobin levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (days)</td>
</tr>
<tr>
<td>Hb (gm/L)</td>
</tr>
</tbody>
</table>

* Hemoglobin after transfusion.

* After rhEp was withheld for 10 days.

The results suggest that during initial rhEp treatment (days 31 to 45 at dose of 100 U/kg SC TIW) and after increase of dose of rhEp (days 46 to 85 at dose of 175 U/kg SC TIW), hemoglobin response was suboptimal. The results suggest that after dose was increased further (days 96 to 116 at dose of 250 U/kg SC TIW), hemoglobin level was more stable.

**Comparison with PK in Adults**

The author compares PK after IV doses in the case report infant with PK in 16 healthy adults after IV doses (results in adults obtained from an article by Flaharty et al).
Flaharty et al study:

Product used: The Flaharty et al study used epoetin beta.

Pharmacokinetic parameter values for adults from the Flaharty et al. study are shown below. (Pharmacokinetic parameter values are taken from page 824 of the Kling et al article.)

<table>
<thead>
<tr>
<th>Mean PK parameters in healthy adults (n=16) (Results from Flaharty et al article reported in Kling et al article)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
</tr>
<tr>
<td>Plasma CL (ml/kg*hr)</td>
</tr>
<tr>
<td>V_{ss} (ml/kg)</td>
</tr>
<tr>
<td>t_{1/2a} (hr)</td>
</tr>
<tr>
<td>MRT (hr)</td>
</tr>
</tbody>
</table>

Compared with the adult data, the Ep PK after IV injection in the neonatal patient showed greater Cl and V_{ss} per kilogram of body weight. The t_{1/2a} in the neonate was similar to the adult mean value.

**PK Results in Another Infant**

In an addendum, the author states that an additional infant with renal failure caused by posterior urethral valves was studied at 29 days of age. Pharmacokinetic parameter values for that patient were included as a footnote in the article and are summarized below. (PK parameter values are taken from page 824 of the Kling et al article.)

<table>
<thead>
<tr>
<th>PK in second infant with renal failure (age 29 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Plasma CL (ml/kg*hr)</td>
</tr>
<tr>
<td>Volume of distribution (ml/kg)</td>
</tr>
<tr>
<td>V_{ss} (ml/kg)</td>
</tr>
<tr>
<td>t_{1/2a} (hr)</td>
</tr>
<tr>
<td>t_{1/2b} (hr)</td>
</tr>
<tr>
<td>MRT (hr)</td>
</tr>
</tbody>
</table>

No further clinical information about this patient is provided. No information about derivation of pharmacokinetic parameters is provided.

**Authors’ Conclusions**

The authors conclude that the initial suboptimal response to rhEp in this patient may have been due to inadequate dosage. This conclusion is supported by a comparison of pharmacokinetic parameters found in the case report infant with pharmacokinetic parameters found in adults in the study by Flaharty et al.
STN 103234/5076
The authors state that the greater Cl and V_{ss} in neonates will result in a lower serum Ep concentration and therefore require a larger dosage.

Reviewer's Comments

The authors state that "recombinant human erythropoietin" was given to the case report infant and the additional infant. It is not clear if the product administered to the infants was epoetin alfa or epoetin beta.

The authors compare the PK in the case report infant with the PK in adults who were given epoetin beta. Epoetin alfa and epoetin beta have the same amino acid sequence but differ in glycosylation; thus the PK of the two products may be different.

If the product administered to the case report infant and/or the additional infant was different from the product administered to the healthy adults, then no conclusions can be drawn about the PK in infants compared to healthy adults.
Widness et al Study


The objectives of the study were to determine if PK differences exist between the following:
1. VLBW infants and normal adults.
2. VLBW infants studied at different postnatal ages.
3. VLBW infants studied before and after chronic rhEPO administration.

The authors examined the first, second, and third objective as follows:
1. First objective: PK parameters were compared between seven premature infants (birth weight < 1.25 kg) and ten normal adults at three escalating doses of IV rhEPO (10, 100, and 500 IU/kg).
2. Second objective: At a dose of 100 IU/kg, PK parameters were compared at 3 and 9 weeks of age in the absence of prior rhEPO treatment.
3. Third objective: At a dose of 100 IU/kg, PK parameters were compared before, and immediately after, 6 weeks of rhEPO treatment.

Study Methods and Results

Methods:

Ten adults and seven rhEPO-treated infants underwent intravenous pharmacokinetic studies at escalating rhEPO doses: 10, 100, and 500 IU/kg.

Infants entry criteria:
Infants entry criteria included birth weights ≤ 1,250 g, gestational age at birth < 31 weeks, hematocrit < 40%, weekly phlebotomy losses < 7.5 mL, stable respiratory status (i.e. arterial O₂ saturation ≥ 85% in an inspired O₂ fraction ≤ 0.30 and a mean airway pressure of ≤ 8 cm H₂O on assisted ventilation), and caloric intake of > 60 kcal/kg/day for ≥ 2 days (≥50% of calories received enterally).

Infants were not eligible for study if they had a severe clinical disease of a major organ system, diastolic blood pressure > 60 mm Hg, treatment with an experimental drug other than surfactant, a history of seizures, anemia due to factors other than prematurity, isoimmunization, intracranial hemorrhage greater than or equal to grade III, congenital or acquired infection, or a major congenital malformation. Those enrolled were required to have a postnatal age of 7 to 28 days if born at 28 to 30 week gestation, 7 to 35 days if born at 27 week gestation, and 7 to 42 days if born at < 27 week gestation.

Adults entry criteria:
Adults enrolled were required to be in good general health and to have normal iron indexes. Adults with acute or chronic illnesses were excluded. Also excluded were those who were anemic (i.e., hematocrit < 36% for women and <
40% for men) or who gave a history of significant blood loss within the previous year, including blood donation.

**Study design:**

**Adults:** All ten adults underwent serial increasing dose IV PK studies.  
**Infants:** Thirteen infants were enrolled. These thirteen were randomized to two groups as follows:

- **EPO group:** Chronic rhEPO treatment  
  7 infants to receive 100 IU/kg SC Q week X 5

- **Placebo group:**  
  6 infants to receive placebo Q week X 5

Serial increasing dose IV PK studies were performed in the EPO group as shown below.

<table>
<thead>
<tr>
<th>EPO group</th>
<th>Scheduled Dose</th>
<th>Administered Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1</td>
<td>100 IU/kg SC</td>
<td>100 IU/kg SC</td>
</tr>
<tr>
<td>Week 2</td>
<td>100 IU/kg SC</td>
<td>100 IU/kg SC</td>
</tr>
<tr>
<td>Week 3</td>
<td>100 IU/kg SC</td>
<td>100 IU/kg SC</td>
</tr>
<tr>
<td>Week 4</td>
<td>100 IU/kg SC</td>
<td>100 IU/kg SC</td>
</tr>
<tr>
<td>Week 5</td>
<td>100 IU/kg SC</td>
<td>100 IU/kg IV†</td>
</tr>
<tr>
<td>Week 6</td>
<td>500 IU/kg IV‡</td>
<td></td>
</tr>
</tbody>
</table>

* First pharmacokinetic study was at 10 IU/kg IV. Dose was administered 1 to 5 days before the scheduled initiation of treatment.  
# Second pharmacokinetic study was at 100 IU/kg IV. Dose took the place of the first regularly scheduled 100 IU/kg SC dose.  
† Third pharmacokinetic study was at 100 IU/kg IV. Dose took the place of the last regularly scheduled 100 IU/kg SC dose.  
‡ Fourth pharmacokinetic study was at 500 IU/kg IV. Dose was administered 1 week after the end of rhEPO treatment.

One PK study occurred in the Placebo group on the last treatment day as shown below.

<table>
<thead>
<tr>
<th>Placebo group</th>
<th>Scheduled Dose</th>
<th>Administered Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1</td>
<td>Placebo SC</td>
<td>Placebo SC</td>
</tr>
<tr>
<td>Week 2</td>
<td>Placebo SC</td>
<td>Placebo SC</td>
</tr>
<tr>
<td>Week 3</td>
<td>Placebo SC</td>
<td>Placebo SC</td>
</tr>
<tr>
<td>Week 4</td>
<td>Placebo SC</td>
<td>Placebo SC</td>
</tr>
<tr>
<td>Week 5</td>
<td>Placebo SC</td>
<td>100 IU/kg IV*</td>
</tr>
</tbody>
</table>

* Pharmacokinetic study was at 100 IU/kg IV. Dose took the place of the last regularly scheduled placebo SC dose.
Product administered: Two lots of 2,000 IU/ml from R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, were administered to the infants, and adults received rhEPO from a single lot of 4,000 IU/mL. No further information about the product provided. Amgen stated in a reply to FDA question about the product used that the source of epoetin alfa used is “to the best of our knowledge, Epogen/Procrit.”

Dosing Summary:
Infants: rhEPO IV Bolus was administered over 1 to 3 minutes. Dose was escalated from 10 IU/kg, to 100 IU/kg, and to 500 IU/kg in the EPO group as described above. Dose of 100 IU/kg was administered to the Placebo group as described above.
Adults: rhEPO IV Bolus was administered over 1 to 3 minutes. Dose was escalated from 10 IU/kg, to 100 IU/kg, and to 500 IU/kg. Dosing was no less frequent than every 2 weeks.

Pharmacokinetics: Samples were assayed for EPO in a radioimmunoassay.
Infants: Capillary blood samples were drawn on 8 to 10 occasions by heel-stick. Urine was collected for EPO determinations after spontaneous voiding in infants.
Adults: A similar number of venous samples were drawn from an indwelling line in the arm opposite the one in which the rhEpo infusion was administered. Urine was collected for EPO determinations every 4 hours in adults.

Pharmacodynamics: Hemoglobin concentrations, hematocrits, and reticulocyte counts were analyzed on whole blood samples. Hemoglobin concentration and hematocrit values were determined using a Technicon H-1 autoanalyzer. Reticulocyte counts were performed using a FACS flow cytometer. Indicators of iron status measured in duplicate on plasma sampled included ferritin, transferring, and iron.
Pharmacokinetics:

PK in VLBW infants compared to PK in adults:

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Mean PK Parameter values</th>
<th></th>
<th>Adults (n=10)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose (IU/kg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CL&lt;sub&gt;0.1-16hr&lt;/sub&gt; [mL/hr*kg]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>45.6</td>
<td>13.1</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>26.3</td>
<td>7.9</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>16.0</td>
<td>6.2</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>One-half Fractional Elimination Time (&lt;0.1hr, 0.5) [hr]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>45.6</td>
<td>13.1</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>26.3</td>
<td>7.9</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>16.0</td>
<td>6.2</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>One-Quarter Fractional Elimination Time (&lt;0.1hr, 0.25) [hr]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>2.68</td>
<td>5.92</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>5.02</td>
<td>10.00</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>6.91</td>
<td>12.9</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>MRT&lt;sub&gt;0.1-16hr&lt;/sub&gt; [hr]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>3.97</td>
<td>5.69</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>4.46</td>
<td>8.19</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>9.68</td>
<td>13.0</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>Distribution volume (&lt;0.1 hr) [mL/kg]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>88.0</td>
<td>49.9</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>93.0</td>
<td>47.6</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
<tr>
<td>500</td>
<td>73.7</td>
<td>43.6</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
</tbody>
</table>

(PK parameter values in the table above taken from Figures 2-6, pp.142-143, Widness et al)

Compared with adults, very low birth weight infants demonstrated significantly greater plasma clearance and distribution volume and significantly shorter fractional elimination rates (FET) and mean residence time (MRT) at all three rhEPO doses. Both infants and adults demonstrated nonlinear EPO elimination, i.e., increasing rhEPO dosing was associated with decreasing plasma clearance and increasing FET and MRT.

PK in VLBW infants before and after rhEPO therapy:

| rhEPO group: Mean PK Parameter values in VLBW infants before and after rhEPO therapy |
|---------------------------------------------|---------------------------------------------|-------|-------|---------|
| PK Parameter                                      | Pre-EPO | Post-EPO | P value |
| Dose (IU/kg)                                       |          |          |         |
| CL<sub>0.1-16hr</sub> [mL/hr*kg]                  | 26.6     | 31.6     | 0.04   |
| One-Quarter Fractional Elimination Time (<0.1hr, 0.25) [hr] | 4.92     | 3.58     | 0.004  |
| MRT<sub>0.1-16hr</sub> [hr]                        | 4.29     | 3.40     | 0.05   |
| Distribution volume (<0.1 hr) [mL/kg]              | 92.8     | 79.7     | 0.033  |

(PK parameter values in the table above taken from Figure 7, pg. 144, Widness et al)
PK in VLBW infants before and after placebo:

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Pre-EPO</th>
<th>Post-EPO</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$CL_{0.1-16h}$ [mL/hr*kg]</td>
<td>26.6</td>
<td>29.4</td>
<td>NS</td>
</tr>
<tr>
<td>One-Quarter Fractional Elimination Time (0.1hr,</td>
<td>4.92</td>
<td>4.33</td>
<td>NS</td>
</tr>
<tr>
<td>0.25)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$MRT_{0.1-16h}$ [hr]</td>
<td>4.29</td>
<td>4.75</td>
<td>NS</td>
</tr>
<tr>
<td>Distribution volume (0.1 hr) [mL/kg]</td>
<td>92.8</td>
<td>90.0</td>
<td>NS</td>
</tr>
</tbody>
</table>

(PK parameter values in the table above taken from Figure 7, pg. 144, Widness et al)

In the absence of rhEPO treatment, there were no pharmacokinetic differences between the two subgroups of infants studied 6 weeks apart. In contrast, the rhEPO-treated infant subgroup demonstrated a significant increase in clearance and a decrease in FET and MRT following 6 weeks of treatment.

Pharmacodynamics:

<table>
<thead>
<tr>
<th>Laboratory data in adults and infants at first PK study (mean ± SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLBW Infants (n=13)</td>
</tr>
<tr>
<td>Normal Adults (n=10)</td>
</tr>
<tr>
<td>Hemoglobin, g/L</td>
</tr>
<tr>
<td>Reticulocytes, $10^9$/L</td>
</tr>
<tr>
<td>Plasma ferritin, ng/L</td>
</tr>
<tr>
<td>Plasma transferrin, ng/L</td>
</tr>
<tr>
<td>Transferrin saturation, %</td>
</tr>
<tr>
<td>Plasma EPO, IU/L</td>
</tr>
</tbody>
</table>

* P<0.001 compared with very low birth weight (VLBW) infants (unpaired t-test)

(Values in table above taken from Table 1, pg. 142, Widness et al)

**Authors’ Conclusions**

The authors state that compared with adults, VLBW infants demonstrated significantly greater plasma clearance and distribution volume and significantly shorter fractional elimination times (FET) and mean residence time (MRT) at all three rhEPO doses. The authors state that both infants and adults demonstrated nonlinear EPO elimination, i.e., increasing rhEPO dosing was associated with decreasing plasma clearance and increasing FET and MRT.

The authors state that in the absence of rhEPO treatment there were no pharmacokinetic differences between the two subgroups of infants studied 6 weeks apart. In contrast, the rhEPO-treated infant subgroup demonstrated a significant increase in clearance and a decrease in FET and MRT following 6 weeks of treatment.

The authors conclude that enhancement of rhEPO efficacy in the prevention and treatment of anemia in premature infants may require higher doses administered in a progressively increasing fashion.
The authors state that the recombinant erythropoietin used was obtained from R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, but do not explicitly state that the product was epoetin alfa. Both adults and premature VLBW infants were administered the same product.

Comparison of the PK parameters between the adults and VLBW premature neonates after IV doses of 10, 100, and 500 IU/kg, suggested that distribution volume is approximately 1.5 to 2 times higher for the preterm VLBW neonates compared to adults, and clearance is approximately 3 times higher for the preterm VLBW neonates compared to adults.
RECOMMENDATIONS

1. The Widness et al study suggested that distribution volume is approximately 1.5 to 2 times higher for the preterm VLBW neonates compared to adults, and clearance is approximately 3 times higher for the preterm VLBW neonates compared to adults. This information should be added to the label.
COMMENTS TO THE SPONSOR

1. The post-marketing commitment has been fulfilled.

2. We propose the following addition to the Pharmacokinetics section of the label:

   Current Label: The pharmacokinetic profile of EPOGEN® in children and adolescents appears to be similar to that of adults. Limited data are available in neonates.  

   Revised Label: The pharmacokinetic profile of EPOGEN® in children and adolescents appears to be similar to that of adults. Limited data are available in neonates.\textsuperscript{17} \textbf{A study of 7 preterm very low birth weight neonates and 10 healthy adults given IV erythropoietin suggested that distribution volume was approximately 1.5 to 2 times higher for the preterm neonates, and clearance was approximately 3 times higher for the preterm neonates.}\textsuperscript{18}

3. We propose that the following reference be added to the label:


Anil K. Rajpal, M.D.
Clinical Pharmacology Reviewer

Martin D. Green, Ph.D.
Associate Director for Pharmacology and Toxicology, ODE VI

10/26/04
10/28/04
Appendix 1

Kling et al study: rhEp Concentration versus Time Curve

rhEp concentration versus time curve is taken from page 823 of the Kling et al article.

Dark circles(*) indicate the PK study at 31 days.
Clear circles(•) indicate the PK study at 103 days.
Appendix 2

Widness et al study: Mean Epo Concentration versus Time Curves

Mean Epo concentration versus time curves are taken from page 142 of the Widness et al article.

Dashed lines (- - -) indicate mean plasma erythropoietin levels in very low birth weight infants (n=13).
Solid lines (-----) indicate mean plasma erythropoietin levels in normal adults (n=10).
DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC,
OR AN ANTIBIOTIC DRUG FOR HUMAN USE
(Title 21, Code of Federal Regulations, Parts 314 & 601)

APPLICATION INFORMATION

NAME OF APPLICANT
Amgen Inc.

DATE OF SUBMISSION
07 October 2004

TELEPHONE NO. (Include Area Code)
805-447-1000

FACSIMILE (FAX) Number (Include Area Code)
805-480-1330

APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, and U.S. License number if previously issued):
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, Ca 91320-1799

AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, ZIP Code, telephone & FAX number) IF APPLICABLE
N/A

PRODUCT DESCRIPTION

NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (if previously issued) BL 103234

ESTABLISHED NAME (e.g., Proper name, USP/NF name)
Epoetin alfa

PROPRIETARY NAME (trade name) IF ANY
Epogen®, Procrit®

CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (if any)
rHuEPO

STRENGTHS: 2,000; 3,000; 4,000; 10,000; 20,000; 40,000 Units/mL

ROUTE OF ADMINISTRATION: IV; SC

(DOSES) INDICATION(S) FOR USE: Treatment of anemic chronic renal failure patients, anemic zidovudine treated HIV infected patients, anemic cancer patients on chemotherapy and surgery patients to reduce the need for allogeneic transfusions.

APPLICATION INFORMATION

APPLICATION TYPE
☐ NEW DRUG APPLICATION (21 CFR 314.50)
☐ ABBREVIATED NEW DRUG APPLICATION (ANDA, 21 CFR 314.94)
☐ BIOLOGICS LICENSE APPLICATION (21 CFR Part 601)

IF AN NDA, IDENTIFY THE APPROPRIATE TYPE ☐ 505 (b)(1) ☐ 505 (b)(2)

IF AN ANDA, OR 505(b)(2), IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION

Name of Drug

Holder of Approved Application

TYPE OF SUBMISSION (Check one)
☐ ORIGINAL APPLICATION
☐ AMENDMENT TO PREVIOUS APPLICATION
☐ RESUBMISSION
☐ PRESHUSSION
☐ ANNUAL REPORT
☐ ESTABLISHMENT DESCRIPTION SUPPLEMENT
☐ EFFICACY SUPPLEMENT
☐ LABELING SUPPLEMENT
☐ CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT
☐ OTHER

IF A SUBMISSION OF PARTIAL APPLICATION, PROVIDE LETTER DATE OF AGREEMENT TO PARTIAL SUBMISSION: N/A

IF A SUPPLEMENT, IDENTIFY THE APPROPRIATE CATEGORY ☐ CBE ☐ CBE-30 ☐ Prior Approval (PA)

REASON FOR SUBMISSION
Labeling Supplement: Post Marketing Commitment, Pharmacokinetics in Neonates

PROPOSED MARKETING STATUS (check one)
☐ PRESCRIPTION PRODUCT (Rx)
☐ OVER THE COUNTER PRODUCT (OTC)

NUMBER OF VOLUMES SUBMITTED 1

THIS APPLICATION IS ☐ PAPER ☐ PAPER AND ELECTRONIC ☐ ELECTRONIC

ESTABLISHMENT INFORMATION (Full establishment information should be provided in the body of the Application.)
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFR), DMF number, and manufacturing steps and/or type of testing (e.g., Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.

N/A

Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BIMs, and DMFs) IDENTIFIED IN THE CURRNT APPLICATION

BL: 103234

RECEIVED
OCT 1 2 2004

CDER/DDR/TBP

FORM FDA 356h (9/02)
This application contains the following items: (Check all that apply)

- 1. Index
- 2. Labeling (check one)  ✔ Draft Labeling  ☐ Final Printed Labeling
- 3. Summary (21 CFR 314.50 (c))
- 4. Chemistry section
  - A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)
  - B. Samples (21 CFR 314.50(e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA’s request)
  - C. Methods validation package (e.g., 21 CFR 314.50(e)(2)(i); 21 CFR 601.2)
- 5. Nonclinical pharmacology and toxicology section (e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)
- 6. Human pharmacokinetics and bioavailability section (e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)
- 7. Clinical Microbiology (e.g., 21 CFR 314.50(d)(4))
- 8. Clinical data section (e.g., 21 CFR 314.50(d)(5); 21 CFR 601.2)
- 9. Safety update report (e.g., 21 CFR 314.50(d)(6)(vi)(b); 21 CFR 601.2)
- 10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)
- 11. Case report tabulations (e.g., 21 CFR 314.50(f)(1); 21 CFR 601.2)
- 12. Case report forms (e.g., 21 CFR 314.50(f)(2); 21 CFR 601.2)
- 13. Patent information on any patent which claims the drug (21 U.S.C. 355(0) or (c))
- 14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355 (b)(2) or (j)(2)(A))
- 15. Establishment description (21 CFR Part 600, if applicable)
- 16. Debarment certification (FD&C Act 306 (k)(1))
- 17. Field copy certification (21 CFR 314.50 (l)(3))
- 18. User Fee Cover Sheet (Form FDA 3397)
- 20. OTHER (Specify)

CERTIFICATION

I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications, warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, including, but not limited to the following:

1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 606, and/or 820.
3. Labeling regulations in 21 CFR Parts 201, 605, 610, 660, and/or 809.
6. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80, and 600.81.
7. Local, state and Federal environmental impact laws.

If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act, I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision. The data and information in this submission have been reviewed and, to the best of my knowledge are certified to be true and accurate.

Warning: A willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.

SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT: [Signature]

TYPED NAME AND TITLE: [Typed Name and Title]

DATE: [Date]

ADDRESS (Street, City, State, and ZIP Code):

[Address]

Telephone Number:

[Telephone Number]

Public reporting burden for this collection of information is estimated to average 24 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services
Food and Drug Administration
9200 Corporate Blvd, Room 5198
Rockville, MD 20852

Food and Drug Administration
CBER: HFD-99
1401 Rockville Pike
Rockville, MD 20852-1448

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
**DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**FOOD AND DRUG ADMINISTRATION**

**PRESCRIPTION DRUG USER FEE COVER SHEET**

See Instructions on Reverse Side Before Completing This Form

A completed form must be signed and accompany each new drug or biologic product application and each supplement. See exceptions on the reverse side. If payment is sent by U.S. mail or courier, please include a copy of this completed form with payment. Payment instructions and fee rates can be found on CDER's website: http://www.fda.gov/cder/pdufa/default.htm

<table>
<thead>
<tr>
<th>1. APPLICANT'S NAME AND ADDRESS</th>
<th>4. BLA SUBMISSION TRACKING NUMBER (STN) / NDA NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen Inc.</td>
<td>BL 103234</td>
</tr>
<tr>
<td>One Amgen Center Drive</td>
<td></td>
</tr>
<tr>
<td>Thousand Oaks, CA 91320-1799</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. TELEPHONE NUMBER (Include Area Code)</th>
<th>5. DOES THIS APPLICATION REQUIRE CLINICAL DATA FOR APPROVAL?</th>
</tr>
</thead>
<tbody>
<tr>
<td>(805) 447-1000</td>
<td>YES □ NO ☑</td>
</tr>
<tr>
<td></td>
<td>IF YOUR RESPONSE IS &quot;NO&quot; AND THIS IS FOR A SUPPLEMENT, STOP HERE AND SIGN THIS FORM.</td>
</tr>
<tr>
<td></td>
<td>IF RESPONSE IS &quot;YES&quot;, CHECK THE APPROPRIATE RESPONSE BELOW:</td>
</tr>
<tr>
<td></td>
<td>☑ THE REQUIRED CLINICAL DATA ARE CONTAINED IN THE APPLICATION.</td>
</tr>
<tr>
<td></td>
<td>☐ THE REQUIRED CLINICAL DATA ARE SUBMITTED BY REFERENCE TO:</td>
</tr>
<tr>
<td></td>
<td>(APPLICATION NO. CONTAINING THE DATA).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. PRODUCT NAME</th>
<th>6. USER FEE I.D. NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epocetin alfa</td>
<td>1132-15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCLUSIONS? IF SO, CHECK THE APPLICABLE EXCLUSION.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT BEFORE 01/01/92 (Self Explanatory)</td>
</tr>
<tr>
<td>☐ THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)(1)(E) OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT (See Item 7, reverse side before checking box.)</td>
</tr>
<tr>
<td>☐ A 505b(2) APPLICATION THAT DOES NOT REQUIRE A FEE (See Item 7, reverse side before checking box.)</td>
</tr>
<tr>
<td>☐ THE APPLICATION IS SUBMITTED BY A STATE OR FEDERAL GOVERNMENT ENTITY FOR A DRUG THAT IS NOT DISTRIBUTED COMMERCIALY (Self Explanatory)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION?</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES ☑ NO ☐</td>
</tr>
</tbody>
</table>

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services  
Food and Drug Administration  
CBER, HFM-99  
1401 Rockville Pike  
Rockville, MD 20852-1448

Food and Drug Administration  
CDER, HFD-94  
and  
12420 Parklawn Drive, Room 3046  
Rockville, MD 20852

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

<table>
<thead>
<tr>
<th>NATURE OF AUTHORIZED COMPANY REPRESENTATIVE</th>
<th>TITLE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Doug Hunt</td>
<td>10/7/2004</td>
</tr>
<tr>
<td></td>
<td>Director, Regulatory Affairs</td>
<td></td>
</tr>
</tbody>
</table>

FORM FDA 3397 (12/03)
A compliance for Amgen Incorporated was completed with the approval of 103234-50 — on September 21, 2004, by Concepcion Cruz of DMPQ. There were no outstanding compliance issues. Please see the compliance check below:

The Investigations and Preapproval Compliance Branch completed a review of the compliance check for Amgen, Longmont, CO. There are no pending or ongoing investigations or compliance actions for Amgen, Longmont, CO that would prevent approval of STN 103234/50 —

A Compliance Check for Amgen Longmont, CO was issued by Colleen Hoyt on Aug 31, 2004, with the following notes:

"Based on the reclassification of the July 12-16, 2004 inspection of Amgen, Longmont, CO, from OAI to VAI, there are no pending compliance actions that would prevent approval of STN ——. Actions taken by Amgen to correct violations noted during the inspection will be verified upon the next GMP inspection conducted by Team Biologics."

In Team Bio's current Workplan there are no planned inspections for Amgen at Longmont, CO in the next 6-months.

Coki Cruz, TL, HFD-323
FDA/CDER/OC/DMPQ
301-827-9013 office
301-827-8909 fax

This e-mail message is intended for the exclusive use of the recipient(s) named above. It may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution or copying is strictly prohibited. If you think you have received this e-mail message in error, please e-mail the sender immediately at cruzc@cdrf.fda.gov.
Date: October 25, 2004

From: Monica Hughes, DRMP/ODEVI/CDER

Subject: 103234-5076 First Committee Meeting

This committee meeting was held by email. This PAS supplement was submitted by Amgen to satisfy their PMC for 103234-1046. Originally, this information was submitted as a final study report under 103234- — The PMC as written under 103234-1046 clearly stated that if FDA felt that labeling changes were necessary this would not be able to be filed as a FSR but rather come in as a labeling supplement.

During a teleconference with Amgen on September 16, 2004, both FDA and Amgen agreed upon the exact wording of the labeling change to incorporate neonate data into the pharmacokinetics section of the label and that the reference citation would be added at the end of the PI.

Dr. Anil Rajpal had written a comprehensive review that included the evaluation of the data and our recommendations as discussed during the September 16, 2004, teleconference. Because of this, we decided to issue an acknowledge and approve letter.

In the meantime, another supplement 103234-1058 was approved which revised the package insert and I asked Amgen to submit an amendment to include this proposed language with the language we just approved from the geriatric supplement. Amgen agreed to submit this as an amendment to 103234- — immediately.
07 October 2004

Earl Dye, PhD, Acting Director
CDER Therapeutic Biological Products Document Room
Center for Drug Evaluation and Research
Food and Drug Administration
12229 Wilkins Avenue
Rockville, MD 20852

Attention: Monica Hughes
Cathryn Lee

Reference: Epoetin Alfa License Application BLA 103234
Labeling Supplement: Post Marketing Commitment
Pharmacokinetics in Neonates

Dear Dr. Dye:

Amgen Inc. herewith submits a revised package insert incorporating the proposed revisions to the language requested by the Agency during a teleconference and via facsimile on 16 September, 2004. The Agency requested the teleconference to seek agreement on the status of the post-marketing commitment covering the literature search for articles pertaining to the pharmacokinetic profile of Epogen in neonates. The Agency requested that Amgen submit a revised package insert and a copy of the Widness et. al. article (Attachment 1) as a prior approval supplement. It was agreed that FDA will attempt to complete review of this supplement by the 19 October action date for

Specifically, the Epogen package insert was revised to reflect the following two additions to the Pharmacokinetics section of the label:

1. Current Label: The pharmacokinetic profile of EPOGEN in children and adolescents appears to be similar to that of adults. Limited data are available in neonates. (17)

   Revised Label: The pharmacokinetic profile of EPOGEN in children an adolescents appears to be similar to that of adults. Limited data are available in neonates. (17) A study of 7 preterm very low birth weight neonates and 10 healthy adults given IV erythropoietin suggested that distribution volume was approximately 1.5 to 2 times higher in the preterm neonates than in the healthy adults, and clearance was approximately 3 times higher in the preterm neonates than in the healthy adults. (44)
2. The following reference be added to the label:


Both redlined and clean versions of the package insert are provided hardcopy and electronically (word and PDF).

Please make this information part of the BLA 103234 file for Epoetin alfa. The information contained herein is proprietary and confidential and should not be disclosed to any third party without the prior written consent of Amgen Inc. Amgen Inc. considers the contents of this submission confidential and exempt from disclosure under 21 CFR§20.61 and Freedom of Information Act 5 USC (b)(4).

Please contact Matthew Neal at (805) 447-6236 regarding any information technology questions or requirements. Should you have further questions or need additional clarification, please contact Donna Peterson at (202) 354-6118.

Sincerely,

Douglas Hunt on behalf of

Director, Regulatory Affairs

2004-10-07 NS EPO PMC AR
LICENSING ACTION RECOMMENDATION

Applicant: Amgen, Incorporated

Product: Epoetin alfa

Indication / manufacturer's change:
Revise the package insert to update the Pharmacokinetics Subsection of the Clinical Pharmacology section to include pharmacokinetic profile of Epoetin alfa in neonates

☐ Approval:
☐ Refusal to File: Memo included
☐ Memo of SBA equivalent reviews included
☐ Denial of application / supplement: Memo included

RECOMMENDATION BASIS

☐ Review of Documents listed on Licensed Action Recommendation Report
☐ Inspection of establishment
☐ Inspection report included
☐ B/Mo inspections completed
☐ B/Mo report included
☐ Review of protocols for lot no.(s)
☐ Test Results for lot no.(s)
☐ Review of Environmental Assessment
☐ FONS included
☐ Categorical Exclusion
☐ Review of labeling
Date completed: 11-1-04
☐ None needed

CLEARANCE – PRODUCT RELEASE BRANCH

☐ CBER Lot release not required
☐ Lot no.(s) in support – not for release
☐ Lot no.(s) for release

Director, Product Release Branch

CLEARANCE – REVIEW

Review Committee Chairperson: [Signature] Date: 11-10-04

Product Office’s Responsible Division Director(s)*:
[Signature] Date: 11-10-2004

DMPQ Division Director*:

* If Product Office or DMPQ Review is conducted

CLEARANCE – APPLICATION DIVISION

☐ Compliance status checked
☐ Acceptable
☐ Hold
Date: 9-21-04
☐ Cleared from Hold
Date: 

Regulatory Project Manager (RPM) [Signature] Date: 11-8-04

Responsible Division Director (where product is submitted, e.g., application division or DMPQ) [Signature] Date: 11-9-04

Form DCC-201 (02/2003)
BLA/NDAA/PMA
Review Committee Assignment Memorandum

STN: 103234-5076

Applicant: Amgen, Incorporated

Product: Epoetin alfa

### Addition of committee members

<table>
<thead>
<tr>
<th>Name</th>
<th>Reviewer Type*</th>
<th>Job Type</th>
<th>Assigned by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monica Hughes</td>
<td>Reg. Project Manager</td>
<td>Admin/Regulatory</td>
<td>K. Jones</td>
<td>10-12-04</td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Admin/Regulatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Product*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Product*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anil Rajpal</td>
<td>Reviewer</td>
<td>Clinical Pharmacology</td>
<td>M. Green</td>
<td>10-12-04</td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Pharm/Tox</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Biostatistics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>BiMo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Safety Evaluator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>CMC, Facility*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Labeling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reviewer</td>
<td></td>
<td>Other</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*add inspector, if applicable

### Deletion of Committee Member

<table>
<thead>
<tr>
<th>Name</th>
<th>Reviewer Type*</th>
<th>Job Type</th>
<th>Changed by</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*reviewer types: chairperson, consultant reviewer, regulatory coordinator, reviewer, and reg. project mgr (RPM)

Submitted by RPM:

Monica Hughes
Name Printed
Signature
Date: 11-1-04

Memo entered in RMS by: [Signature] Date: 11/2/4 QC by: [Signature] Date: 1/2/04